Elucidating the spatial and temporal immune response to immunomodulatory materials by Baker, Nusaiba F.
ELUCIDATING THE SPATIAL AND TEMPORAL IMMUNE 



























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 








Georgia Institute of Technology 
May 2020 
 
COPYRIGHT © 2020 BY NUSAIBA BAKER 
 
 
ELUCIDATING THE SPATIAL AND TEMPORAL IMMUNE 

















Dr. Edward Botchwey, PhD, Co-Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Gabriel Kwong, PhD 
School of Biomedical Engineering 




Dr. Andrew Neish, MD, Co-Advisor 
Department of Pathology 
Emory University School of Medicine 
 Dr. Robert Gross, MD, PhD 
School of Biomedical Engineering 




Dr. Julie Champion, PhD 
School of Chemical and Biomolecular 
Engineering  
Georgia Institute of Technology 
  
 
   












When I started MD/PhD at Emory, I had no idea what was to come. Graduate school has 
been the biggest challenge of my life, and I have learned so much more than just science over 
these last few years. That being said, none of this was possible without the incredible support and 
amazing people I have met along the way. There are so many people who helped and encouraged 
me, who taught me techniques and skills, and who simply were kind to me during my time of 
need. I wrote this section of my thesis at the same time that the legendary Kobe Bryant passed 
away, and it made me reflect on the importance of life and its fragility. I am so thankful to 
everyone who supported me, who inspired me, and who pushed me to complete both my MD and 
PhD. This work is dedicated to Kobe, whose Mamba Mentality taught me to work hard and chase 
my dreams. 
First, I have to thank my family. I am so thankful to my parents, who have been the most 
supportive and most caring people throughout this journey. Without their hard work, dedication, 
passion, and drive, Hanan and I wouldn’t be who we are or where we are today. I am also 
thankful to my sister, Hanan, whose fearlessness and intelligence earned her a spot at the Weill 
Cornell MD/PhD program, and who defended her PhD before me. Her thoughtfulness as a 
scientist and human being inspires me beyond anyone I have ever met. 
I am also extremely thankful to my advisors, Dr. Andrew Neish and Dr. Edward 
Botchwey. Dr. Neish has been an incredibly supportive advisor, who was always there when I 
needed science advice or personal advice. Dr. Neish was always in my corner, whether it was 
moving my projects forward, or supporting my career aspirations. Dr. Neish is a great listener and 
is the reason why I stayed in science when times were hard. His dedication to making sure I was 
doing my best inspired me to make him proud. I cannot thank him enough for welcoming me into 
his lab and making sure I graduated with both an MD and a PhD.   
 v 
Dr. Edward Botchwey has been an incredible mentor and source of inspiration. Joining 
his lab was one of the biggest blessings that could have happened in my career. Beyond 
immunology and biomaterials, I was fortunate to be exposed to computational techniques that 
added more depth to my graduate training than I thought possible. Dr. Botchwey’s suggestions 
and advice were always invaluable, and he was always thinking ahead on how to best represent 
and characterize our data. His influence will always be with me, even as I move onto a career in 
surgery.  
 I owe my utmost gratitude to my thesis committee, which includes Dr. Julie Champion, 
Dr. Gabriel Kwong and Dr. Robert Gross. Their support and insight has been invaluable and truly 
changed the trajectory of my graduate career for the better. Their feedback at my thesis proposal 
was instrumental to helping me identify areas where I needed to improve. Every suggestion was 
monumental to helping me develop a framework for asking questions and focus my thesis work. 
Without them, it is unlikely that this document would have been written.   
 I owe much of my gratitude to Arielle, Amanda, and Stephanie. I never imagined I would 
meet a group of women in MD/PhD who are so much like me. I am so thankful to have friends 
who understood every aspect of what I was going through. I could not imagine a better group of 
friends with whom to take on these eight years. 
 I am also indebted to the incredible mentors I have had over the years. Kornelia Galior 
was my first mentor, and she was beyond inspirational. She was able to do anything she put her 
mind towards, and her infectious smile and joy for life made going to lab so worth it. Kim Clarke 
was also a close friend and advisor, who spent countless hours helping me organize my thoughts 
and guiding me in creating powerful presentations. Bridgette Peake was also a huge source of 
inspiration, and I am so grateful to have worked alongside such a strong and confident woman so 
early in my career. 
I am very grateful to have the opportunity to pursue my graduate career at a school like 
Georgia Tech. The Biomedical Engineering program is unrivaled in the quality of research and 
 vi 
the opportunity to collaborate. There are many people who helped me along the way, whose 
kindness and responsiveness helped me gain the confidence in techniques to move my project 
forward.  
My labmates and close friends in the Botchwey lab, Claire McClain, Lauren Hymel, Dre 
Deveaux, and Thomas Turner are some of the most inspiring, talented, intelligent people I have 
ever met. I am so excited to see what amazing things they accomplish, how many accolades they 
all receive, and what high-impact papers they publish. I am so blessed to have spent time with 
and learn from them. Spending every day in their company brought me so much joy. I wish I 
could capture that feeling forever. 
 The Neish lab has the kindest, most incredible friends and scientists I have ever had the 
pleasure of working with. Bejan Saeedi, Josh Owens, Brian Robinson, Sarah Hunter-Chang, and 
Huixia Wu are, by far, the most creative, most innovative people I have ever met. Bejan, Josh, 
Sarah, and Brian were always willing to help me out, listen to my science ideas (even when my 
ideas involved giving traumatic brain injury to Drosophila), and do whatever it took to move 
science forward. These individuals will be the great PIs of the future, and I am so excited to see 
what they accomplish.  
 I am also eternally grateful to Ian Miller and Elda Treviño, whose passions for life and 
science influenced me daily. Our weekly lunches were one of the main drivers for getting me 
through the last year of my PhD. 
 I am also thankful for everyone at Georgia Tech who was willing to go out of their way 
to show me how to use equipment or teach me new techniques. Sommer Durham is one of the 
kindest people that I have the pleasure of working with, and she was always responsive and 
willing to help me in my time of need. Dr. Laura O’Farrell and Dr. Richard Noel were also very 
understanding, and their passion for their work inspired me with mine. I particularly appreciate 
Dr. O’Farrell going out of her way to teach me how to collect blood from a rat jugular vein. Her 
guidance will stay with me as I complete my PhD and return to medical school. 
 vii 
 I would also like to thank my PSRC mentor, Dr. Justine Lee, whose influence as a 
successful surgeon-scientist inspires my career in science. I felt motivated by her successes, and 
























TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ................................................................................... IV 
LIST OF TABLES ................................................................................................ XI 
LIST OF FIGURES ............................................................................................. XII 
LIST OF SYMBOLS AND ABBREVIATIONS ................................................... XIII 
SUMMARY ......................................................................................................... XV 
CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS ......................................... 1 
1.1 Introduction ....................................................................................................................... 1 
1.2 Specific Aims .................................................................................................................... 1 
Aim 1. Evaluation of pro-regenerative innate and adaptive immune cell recruitment to 
areas of injury following administration of dual-loaded immunomodulatory hydrogels. .. 2 
Aim 2. Elucidation of the local and systemic effects on the immune response following 
oral gavage of immunomodulatory microparticles ................................................................ 2 
Aim 3. Development of nanoparticle-based immune modifiers for the treatment of Th2-
mediated disease ....................................................................................................................... 3 
1.3 Significance ....................................................................................................................... 4 
CHAPTER 2. BACKGROUND ............................................................................... 5 
2.1 Roles of the Immune System in Healing and Disease ................................................... 5 
2.1.1 Phases of wound healing ............................................................................................... 5 
2.1.2 Intestinal damage and healing ........................................................................................ 7 
2.2 Role of the Innate Immune System ................................................................................. 8 
2.2.1 Neutrophils play several roles in the inflammatory cascade ........................................... 8 
2.2.2 Macrophages are an important mediator between innate and adaptive immunity ....... 11 
2.3 Role of the Adaptive Immune System ........................................................................... 12 
2.4 The interface between biomaterials and immunology ................................................ 14 
2.4.1 Novel molecular therapies for IBD ................................................................................ 15 
2.4.2 Polysaccharide-based materials ................................................................................... 17 
2.5 Using dimensionality reduction techniques to elucidate cellular heterogeneity in 
data 20 
CHAPTER 3. DUAL DELIVERY OF IL-10 AND AT-RVD1 FROM RGD-
FUNCTIONALIZED PEG HYDROGELS POLARIZE IMMUNE CELLS 
TOWARDS PRO-REGENERATIVE PHENOTYPES .......................................... 25 
 ix 
3.1 Introduction ..................................................................................................................... 25 
3.2 Results ............................................................................................................................. 28 
3.2.1 Engineering immunomodulatory hydrogels to promote resolution and immune 
polarization ................................................................................................................................ 28 
3.2.2 Anti-inflammatory macrophages and dendritic cells accumulate after local 
immunomodulatory hydrogel delivery ........................................................................................ 32 
3.2.3 Dimensionality reduction analysis reveals trends in innate immune cell heterogeneity 
by day 7 ..................................................................................................................................... 36 
3.2.4 Characterization of Dendritic Cell Recruitment Dynamics using SPADE ..................... 36 
3.2.5 T-cell recruitment dynamics in the dorsal tissue ........................................................... 40 
3.2.6 SPADE analysis reveals trends towards unexpected pro-regenerative adaptive 
immune cell population at day 7 following dual treatment with IL-10+AT-RvD1 ....................... 40 
3.3 Discussion ....................................................................................................................... 44 
3.4 Materials and Methods ................................................................................................... 48 
3.4.1 Thiolation of IL-10 ......................................................................................................... 48 
3.4.2 Hydrogel Fabrication .................................................................................................... 48 
3.4.3 Tissue Harvest and Flow Cytometry ............................................................................. 49 
3.4.4 SPADE analysis of flow cytometry data ....................................................................... 50 
3.4.5 Statistical Analysis ........................................................................................................ 50 
CHAPTER 4. INVESTIGATING THE LOCAL AND SYSTEMIC EFFECTS ON 
THE IMMUNE RESPONSE FOLLOWING ORAL GAVAGE OF 
IMMUNOMODULATORY MICROPARTICLE TREATMENT .............................. 51 
4.1 Introduction ..................................................................................................................... 51 
4.2 Results ............................................................................................................................. 56 
4.2.1 AvrA MPs reduce local innate immunity in the gastrointestinal system ........................ 56 
 ................................................................................................................................................... 58 
4.2.2 AvrA reduces local adaptive immunity in the gastrointestinal system .......................... 59 
4.2.3 Local delivery of oral AvrA microparticles likely do not acutely affect systemic immunity
 60 
4.2.4 Marker expression heatmaps allow for phenotype interpretation ................................. 62 
4.2.5 Node distribution shows different proportions in AvrA Peyer’s patches compared to 
controls 65 
 ................................................................................................................................................... 67 
4.2.6 Salmonella LPS induces both systemic and gastrointestinal inflammation .................. 69 
4.2.7 LPS derived from S. Typhimurium induces gastrointestinal and systemic inflammation
 72 
4.3 Discussion ....................................................................................................................... 74 
4.4 Methods ........................................................................................................................... 77 
4.4.1 Synthesis of AvrA nanoparticles ................................................................................... 77 
4.4.2 AvrA and eGFP Nanoparticle Synthesis ....................................................................... 77 
4.4.3 Nanoparticle characterization ....................................................................................... 77 
4.4.4 Microfluidic device preparation ..................................................................................... 78 
4.4.5 Microparticle fabrication ................................................................................................ 78 
4.4.6 LPS stimulation of C57bl/6 mice ................................................................................... 79 
4.4.7 RT-PCR ........................................................................................................................ 79 
4.4.8 Tissue Harvest and Flow Cytometry ............................................................................. 80 
 x 
4.4.9 SPADE analysis ........................................................................................................... 81 
4.4.10 Statistical analysis .................................................................................................... 82 
CHAPTER 5. DEVELOPMENT OF NANO-PARTICLE BASED IMMUNE 
MODIFIERS FOR THE TREATMENT OF TH2-MEDIATED DISEASE .............. 83 
5.1 Introduction ..................................................................................................................... 83 
5.2 Results ............................................................................................................................. 90 
5.2.1 In silico GATA3 DNAzyme screen ................................................................................ 90 
5.2.2 DzNPs regulation of GATA3 gene ................................................................................ 93 
5.2.3 Investigate DzNP-mediated delivery to the lungs of an animal model ......................... 93 
5.2.4 Determine biodistribution of fluorescently tagged DzNP versus soluble Dz to elucidate 
the pattern of uptake in immune cells and resident lung cells. .................................................. 97 
5.2.5 Determine 2251-DzNP efficacy in a Th2-mouse model ............................................. 104 
5.2.6 Determine efficacy of orally delivered DzNP using an alginate hydrogel delivery 
method. .................................................................................................................................... 104 
5.2.7 Evaluate DzNP distribution within the intestinal villi, characterizing the role of intestinal 
epithelial cells (IECS), gut-associated lymphoid tissue (GALT), and immune cells in particle 
uptake. 107 
5.2.8 Evaluate efficacy of orally delivered GATA3 and TNF-a DzNPs in a mouse model of 
colitis. 110 
5.3 Discussion ..................................................................................................................... 114 
5.4 Methods ......................................................................................................................... 118 
5.4.1 In silico screen of DzNP ............................................................................................. 118 
5.4.2 IVIS imaging ............................................................................................................... 118 
5.4.3 Biodistribution of AuNP in the lung ............................................................................. 119 
5.4.4 Th2 animal model of asthma ...................................................................................... 121 
5.4.5 Oral gavage and gastrointestinal flow cytometry ........................................................ 121 
5.4.6 In vivo DSS colitis mouse model ................................................................................ 122 
5.4.7 Tissue Harvest and Flow Cytometry ........................................................................... 122 
5.4.8 Statistical analysis ...................................................................................................... 123 
CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS ........................... 124 
6.1 Overall summary ........................................................................................................... 124 
6.2 Characterization of innate and adaptive immune cell function in inflammatory 
mouse models ............................................................................................................................ 126 
6.3 Further characterization of immune modulation using dimensionality reduction 
techniques .................................................................................................................................. 128 












Table 1 RT-PCR Primers for Inflammatory Cytokines 
 
80 





Table 2 Lung flow cytometry panel 
 
120 
   




LIST OF FIGURES 
Figure 1. Hydrogel synthesis. ........................................................................................... 31 
Figure 2. Anti-inflammatory macrophages and dendritic cells accumulate after local 
immunomodulatory hydrogel delivery. ............................................................................ 35 
Figure 3. Trends in macrophage heterogeneity in response to immunomodulatory 
hydrogels. .......................................................................................................................... 38 
Figure 4 Trends in dendritic cell heterogeneity in response to immunomodulatory 
hydrogels. .......................................................................................................................... 39 
Figure 5. Adaptive immune response to immunomodulatory hydrogels. ......................... 42 
Figure 6 SPADE trees were developed following flow cytometric analysis to identify rare 
cell subsets. ....................................................................................................................... 43 
Figure 7. AvrA microparticle synthesis. ........................................................................... 55 
Figure 8 Treatment with AvrA influences the innate immune system following E. coli 
LPS stimulation. ................................................................................................................ 58 
Figure 9 Treatment with AvrA influences adaptive immunity. ........................................ 60 
Figure 10. Effects of orally administered AvrA likely do not result in systemic 
immunosuppression. ......................................................................................................... 62 
Figure 11. Expression of phenotypic markers used for node characterization. ................ 64 
Figure 12 SPADE allows for the identification of characteristic immune populations. ... 67 
Figure 13  SPADE allows for the quantification of known and rare immune cell subsets.
........................................................................................................................................... 68 
Figure 14. In vivo inflammatory response to E. coli and S. typhimurium. ...................... 70 
Figure 15. Increased inflammatory cell recruitment induced by Salmonella LPS in the 
IELs is reduced by AvrA MP treatment. .......................................................................... 71 
Figure 16. LPS from S. Typhimurium induces a robust systemic immune response ....... 73 
Figure 17. In silico Dz screen reveals 48 possible sequences. .......................................... 89 
Figure 18 DzNP synthesis and catalytic efficiency. ......................................................... 92 
Figure 19. Intranasal (IN) versus oropharyngeal (OP) administration of AuNP. ............. 96 
Figure 20. Intranasal administration of ATTO647-AuNP Or ATTO647-soluble DNA 
results in differential uptake by immune and epithelial cells. .......................................... 98 
Figure 21. Intranasal administration of ATTO647-AuNP or ATTO647-soluble DNA 
following HDM sensitization results in differential cell uptake. .................................... 101 
Figure 22. DzNP 2251 reduces airway resistance and Th2-related cytokines in mouse 
model of asthma. ............................................................................................................. 103 
Figure 23. DzNP localization to the colon following oral delivery. ............................... 106 
Figure 24. Alginate hydrogel delivery of DzNPs for GI cell uptake .............................. 109 
Figure 25. Hydrogel delivery of GATA3 and TNF DzNPs alleviates inflammation in DSS 
colitis mouse model. ....................................................................................................... 111 
Figure 26. Hydrogel delivery of GATA3 and TNF DzNP alleviates inflammation in a 
DSS model of colitis. ...................................................................................................... 113 
  
 xiii 
LIST OF SYMBOLS AND ABBREVIATIONS 
ANOVA Analysis of Variance 
BSA Bovine serum albumin 






C-X-C chemokine receptor 4 
Dendritic cell 



















Dorsal skinfold window chamber 
Extracellular matrix 
Fetal bovine serum 
Fibroblast growth factor 
Forward scatter 







Mer receptor tyrosine kinase 
Milligram per kilogram 
Matrix metalloprotease 
Classically activated inflammatory macrophage 
Alternatively activated macrophages 

















Phosphate buffered saline 
Poly(ethylene glycol) 
4-arm poly(ethylene glycol)-maleimide 
Poly(lactic-co-glycolic acid) 
Peyer’s patches 
Radical oxygen species 
Side scatter 
Standard error of the mean 
Small intestine 
T-helper  
Tumor necrosis factor 




Immune pathology is characterized by the dysregulation of cellular homeostasis. 
The immune system works as complex network between effector and regulatory 
pathways that balance pro- and anti-inflammatory signals to maintain homeostasis within 
the body. In normal inflammatory processes, the transition between the initial 
inflammatory response to the subsequent proliferative phase is an important one, and 
dysregulation of this process can lead to poor clinical outcomes. When immune cells are 
unable to mount an appropriate immune response, particularly to a self-antigen, 
inflammatory disorders and autoimmunity can ensue. 
Immune modulation therapy has come to the forefront of basic science and 
clinical research to either interrupt immune dysregulation or induce a specific immune 
response. In order to develop novel therapies for targeting the underlying immune 
processes of inflammatory conditions, it is necessary to elucidate the disease etiology and 
cellular signals involved in disease progression. The purposeful manipulation of immune 
cell fates could therefore be useful for promoting an immune response or inhibiting 
inflammation and promoting healing. Biomaterial-based delivery of therapeutics is one 
method to enable localized and targeted modulation of the immune system.  
This dissertation presents the results of using biomaterials delivery of therapeutic 
factors to exploit endogenous mechanisms of innate and adaptive immunity to alleviate 
inflammation and promote the healing response. We hypothesized that biomaterial-based 
delivery of therapeutics are effective treatments to induce local immunomodulation in 
both acute and chronic models of inflammation. First, we used flow cytometry to 
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characterize the spatial and temporal cellular responses to these materials. The analysis 
of flow cytometry data, however, is subject to some bias, and requires detailed 
knowledge of underlying cellular phenotypes. Thus, we next employed Spanning-tree 
Progression Analysis of Density-normalized Events (SPADE), a computational technique 
for the elucidation of multi-dimensional data. SPADE is able to create a 2D visualization 
of complex datasets in a branched “tree” without much needed oversight from the user. 
The usage of this technique allows for the identification of cellular hierarchy, as well as 
rare events, among subpopulations of immune cells. We identified the 
unexpected involvement of adaptive immune cell populations in response to 
immunomodulatory therapeutics. Investigation of the spatial and temporal distribution of 
innate and adaptive immunity at different stages of immunomodulation reveals variations 
in the local microenvironment that may be manipulated to enhance therapeutic 
development. These data suggest that the importance of local biomaterial influence of 
specific cellular subsets and demonstrated the importance of analytical techniques like 
SPADE for elucidating cellular heterogeneity.  
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CHAPTER 1. INTRODUCTION AND SPECIFIC AIMS 
1.1 Introduction 
Normal healing consists of three main phages: the inflammatory phase, the proliferative 
phase, and the remodeling phase(1). The inflammatory phase begins with the recruitment of 
innate immune cells, such as macrophages and neutrophils, to clear debris and prevent 
infection(2). The transition to the proliferative phase is an important one, with macrophages 
taking on a pro-regenerative phenotype, characterized as M2 “alternatively-activated” 
macrophages, and increased expression of anti-inflammatory cytokines(3). Dysregulation of 
immune homeostasis leads to inflammatory disorders and autoimmune disease. Such diseases, 
including rheumatoid arthritis, systemic lupus erythematosus, and ulcerative colitis, are a burden 
to humans because of debilitating illness, high costs for medication, and increased risk of 
mortality. Current treatments, including small molecule inhibitors and steroids, are often 
administered systemically by injection, reducing patient compliance. Additionally, these 
medications are non-specific and frequently result in off-target effects(4).  
The immune system is a finely regulated and controlled interplay between activators and 
inhibitors. In response to an external stimulus, the innate immune system responds to get rid of 
the pathogen. Tissue engineering as a field has developed biomaterials as scaffolds to modulate or 
influence the immune response. These scaffolds are carefully selected with ideal chemical and 
mechanical properties, as well as their biocompatibility with the system of interest(5, 6). Our 
approach is to engineer biocompatible, yet degradable biomaterial scaffolds to temporally and 
spatially target the immune system. Moreover, we will use dimensionality reduction techniques to 
elucidate and better understand the contributions from individual cell populations of the innate 
and adaptive immune systems.   
1.2 Specific Aims 
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Aim 1. Evaluation of pro-regenerative innate and adaptive immune cell recruitment to areas 
of injury following administration of dual-loaded immunomodulatory hydrogels.  
Aim 1 aims to quantify in vivo changes in the recruitment dynamics and differentiation 
status of immune cells after delivery of hydrogels. Here, we developed a PEG-hydrogel system 
that releases IL-10 and AT-RvD1 at the site of injury using the dorsal skinfold window chamber 
mouse model. Following delivery, we characterize the spatial and temporal changes in the 
immune response. We hypothesize that combined delivery of IL-10 and AT-RvD1 can tune the 
immune response after injury and recruit and polarize anti-inflammatory, pro-regenerative subsets 
of macrophages and dendritic cells. In Aim 1A, we characterize the manufacturing of AT-RvD1 
and IL-10 dual hydrogels. In Aim 1B, we implant hydrogels using the dorsal skinfold window 
chamber mouse model and isolate individual cell populations by flow cytometry at day 1, day 3, 
and day 7 following hydrogel delivery. Importantly, control and therapeutic hydrogels are 
delivered into the same mouse; thus, each therapeutic has its own internal control for comparison. 
In Aim 1C, we assess cell phenotypes recruited to the hydrogel by SPADE analysis. This 
dimensionality reduction technique was selected to elucidate the roles of both innate and adaptive 
immunity in the healing response to hydrogels.  
 
Aim 2. Elucidation of the local and systemic effects on the immune response following oral 
gavage of immunomodulatory microparticles 
Inflammatory bowel diseases (IBD) affect five million people worldwide. IBD includes 
Crohn’s disease and ulcerative colitis, two inflammatory disorders that can range from mild to 
severe. If IBD is poorly controlled, it can progress lead to a more severe disease, which can cause 
debilitating pain, bleeding, and in the case of ulcerative colitis, patients have a high likelihood of 
developing cancer. Areas of chronic gastrointestinal inflammation are driven by hyper reactive 
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autoimmune cells producing inflammatory cytokines that can lead to damage of the local 
tissue(7). In this aim, we use previously developed alginate and chitosan microparticles to deliver 
Salmonella AvrA to the site of inflammation(8). AvrA is an effector protein utilized by 
Salmonella to modify and block activation of transcriptional activation of a number of 
inflammatory effector genes(9). The anti-inflammatory properties make AvrA a promising 
therapeutic for the amelioration of inflammation. We hypothesize that microparticle treatment 
will result in inhibition of innate immunity in the Peyer’s patches. 
Specific aim 2A is to elucidate the immune response to AvrA microparticles locally in 
both small intestine and in gastrointestinal lymphoid tissue (GALT). Specific Aim 2B is to utilize 
SPADE to identify characteristic leukocyte populations, as well as rare subsets. Aim 2C is to 
investigate the systemic effects of AvrA microparticles. These data will allow us to determine the 
spatial response to treatment with AvrA particles in an acute model of systemic inflammation.  
 
Aim 3. Development of nanoparticle-based immune modifiers for the treatment of Th2-
mediated disease  
A main cause of inflammatory symptoms is the release of cytokines by circulating immune 
cells from both the innate and adaptive immune systems in response to a stimulus. In some cases, 
dysregulation of the adaptive immune response can be the major driver of disease. The T-helper 
cells (Th cells), also known as CD4+ cells, are a type of cell involved in the adaptive immune 
response, depending on which helper subtype is activated(10). Th1 polarized cells are responsible 
for intracellular pathogens. Th2 cells are important in the defense against helminths and some 
allergic reactions. Th17 cells are a subset that have been linked to several inflammatory 
conditions(10).  The production of cytokines by Th2 cells underlies the inappropriate immune 
response found in some inflammatory and autoimmune disorders, such as ulcerative colitis(11).  
GATA3 is a transcription factor that is a major factor involved in Th2 differentiation and 
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activation (12) and has been found to be upregulated in biopsies and serum from patients with 
inflammatory diseases (13). Therefore, methods to suppress GATA3 expression are being 
actively pursued as a potential therapy to ameliorate chronic inflammation. We hypothesize that 
DzNPs are an effective method of regulating intracellular GATA3, leading to reduction of Th2-
specific cytokines.  Aim 3A will investigate DzNP-mediated GATA3 regulation in a Th2 asthma 
model. Aim 3B will determine efficacy of orally delivered DzNP using an alginate hydrogel 
delivery method. Using a mouse model of colitis, we will evaluate efficacy of orally delivering 
GATA3 and TNF-a DzNPs.  
1.3 Significance 
The use of biomaterials for the local delivery of immunomodulatory factors in an 
unexplored area that has the potential to be applied to a number of different fields. Our proposed 
research uses different biomaterials to specifically deliver therapeutics to the site of injury. In the 
case of aim 1, the combination of IL-10 and AT-RvD1 aims to not only resolve inflammation but 
polarize the local immune microenvironment into anti-inflammatory phenotypes. Moreover, aim 
2 utilizes a bacterial protein to specifically target the inflamed gastrointestinal tract, and locally 
reduce inflammation at the cellular level. Finally, aim 3 employs a DNA-based technology to 
inhibit a pro-inflammatory transcription factor and alleviate the actions of a specific subtype of T-
cell. Moreover, this work is benefitted by the usage of SPADE, a dimensionality reduction 
technique that allowed for the characterization of the local and systemic immune response to 
treatment. SPADE was instrumental in creating a big-picture view of how the therapeutic was 
influencing the immune system at a cellular level, but also in elucidating the role of some cell 
populations that we would not have found by traditional flow cytometry techniques. 
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CHAPTER 2. BACKGROUND 
2.1 Roles of the Immune System in Healing and Disease 
The immune system detects and eliminates foreign pathogens, tumor cells, and 
other invading factors, in order to maintain homeostasis(14). The immune system is a 
network of cells and signaling pathways that eliminate pathogens and infected cells and 
keep effector cells under control under physiological conditions(15). In order to contain 
infection by a pathogen, the initial response by the innate immune cells results in an 
inflammatory response to activate and recruit the appropriate types of cells to eliminate 
it(16). In the event that inflammatory signaling becomes dysregulated, however, the 
cellular signals can result in damage to the body’s own tissues. In fact, inflammation is a 
major problem in human diseases, such as rheumatoid arthritis and inflammatory bowel 
disorders (IBD), wound healing, infection, and cancer(17, 18). Impaired wound healing 
after surgical procedures is one of the most common complications arising from impaired 
immune function due to systemic immunosuppression(19, 20). Any environment with 
excessive cytokine and chemokine production can lead to a persistent immune response 
and subsequent impaired wound healing in the context of injury or infection. Moreover, 
this type of environment may potentially lead to the development of inflammatory 
syndromes or autoimmune disease. The management of chronic wounds and chronic 
inflammatory conditions poses an enormous economic burden on patients and the 
healthcare system. Thus, it is imperative to develop novel therapeutic techniques to 
reduce inflammation and redirect the immune cells towards resolution(21, 22). 
2.1.1 Phases of wound healing 
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Wound healing involves a careful cascade of cells and signals following injury. 
Wound healing is broken up into three main phases: the inflammatory phase, the 
proliferative phase, and the maturation/remodeling phase(23-27). Following initial injury, 
coagulation pathways are activated and result in stopping the outpouring of blood(28). 
Specific coagulation factors also signal to platelets, causing platelet clotting and 
subsequent thrombosis(29). Initial vasoconstriction is quickly followed by vasodilation in 
order to allow for leukocyte recruitment and entry to the site of injury(30). 
The inflammatory phase begins as white blood cells and thrombocytes are recruited 
and begin to secrete inflammatory mediators and cytokines(31). These factors include 
platelet-derived growth factor (PDGF), serotonin, histamine, fibroblast-growth factor 
(FGF), among others(32, 33). PDGF attracts fibroblasts, and, with transforming growth 
factor (TGF) enhances the proliferation of fibroblasts, which are then able to produce 
collagen to replenish the damaged ECM(29, 34). Crucial to the inflammatory phase is the 
immediate response by cells from the innate immune system. Neutrophils, monocytes, 
and endothelial cells adhere to the fibrin scaffold that is set by platelet activation 
following tissue injury(35). This allows for neutrophils and macrophages to phagocytose 
cellular debris, preventing infection of the wound(36). Interestingly, some studies have 
suggested that the adaptive immune system may also play a more significant role in the 
healing process(19). Because of the contributions of different immune cell types at 
different phases of the healing cascade, there exists an opportunity to exploit the intrinsic 
mechanisms of repair in a variety of contexts.  
The proliferative phase begins after 6-7 days, and by a week following injury, 
fibroblasts have begun to lay down new collagen and glycosaminoglycans(37). Re-
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epithelialization and neovascularization begin to occur, forming new vessels and cells to 
bridge the wound. As the wound matures, and more collagen is deposited, the wound 
starts to contract. The maturation phase starts by week 3, and the wound undergoes 
progressive remodeling, which can continue for many years. Matrix metalloproteases 
(MMPs) and tissue inhibitor of metalloproteinase (TIMPs) play important roles in 
developing and remodeling the ECM(38). Collagen type III is eventually replaced by 
collagen type I, which is more oriented and reorganized into a lattice made up of 
glyocsaminoglycans and proteoglycans(39).  
2.1.2 Intestinal damage and healing 
Damage and impairment of the intestinal barrier are observed in a number of 
diseases. The integrity of the intestinal barrier allows for luminal bacteria to 
communicate with the immune system(40). Permeation of the epithelial barrier results in 
the absorption of toxic and immunogenic factors that cause inflammation and 
disequilibrium of host homeostasis(41). The gastrointestinal tract is constantly exposed to 
various antigens, such as enteric bacteria and food. Following injury, the intestinal 
epithelium undergoes a wound healing process(42). Intestinal wound healing depends on 
the migration and proliferation of epithelial cells at the site of injury (43). Previous 
studies have shown that growth factors, cytokines, and the activation of specific signaling 
pathways are involved in intestinal epithelial wound healing(41, 44, 45).  
The etiology of IBD remains unknown, but it has been suggested that disruption of 
the intestinal barrier and repeated intestinal epithelial damage are highly implicated to be 
involved in disease pathogenesis and severity(41, 46). As a result, the integrity of the 
epithelial layer is damaged, which results in aberrant immune cell activation. In both 
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innate and adaptive immunity, the disruption of mechanisms of regulation may lead to 
abnormal immune responses to foreign antigens and result in chronic inflammation. In 
this context, it has been suggested that therapeutic strategies should focus on improving 
the wound healing response of the intestinal epithelium or reducing the inflammation 
caused by the immune system(42). 
2.2 Role of the Innate Immune System 
The innate immune system plays an important role in maintaining homeostasis and 
restoring homeostasis following tissue injury or infection. In the context of infection, the 
immediate response of the innate immune system is to mount a rapid, non-specific 
defense to foreign pathogens(5, 19). Typically found on such pathogens are molecular 
patterns that stimulate individual cells to identify a target as foreign, and either 
immediately remove it, or signal to the adaptive immune system to activate a more 
specific immune response(16, 47).  
Infections and similar inflammatory mechanisms are first accompanied by a rapid 
influx of neutrophils from the periphery to the site of inflammation(48). These cells kill 
microorganisms, clear infections, and recruit the necessary immune cells. Their ability to 
kill and clear infections depends on different mechanisms, such as chemotaxis, 
phagocytosis, and release of reactive oxygen species (ROS) (49, 50). 
2.2.1 Neutrophils play several roles in the inflammatory cascade 
Neutrophils, also known as polymorphonuclear (PMN) leukocytes, are the most 
abundant cell type in humans, produced in the bone marrow at 1011 per day(51). The 
maintenance of neutrophil homeostasis is achieved by balancing short lifespans with 
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regular release from bone marrow. These cells enter circulation and complete their 
functions in various tissues before being removed by macrophages at the end of the day. 
Interestingly, macrophages take on anti-inflammatory phenotypes after phagocytosing 
apoptotic neutrophils(52). Their functions include patrolling for signs of infection, 
following which they trap and eliminate foreign pathogens(53). Neutrophils respond to 
multiple signals, by causing the production of several cytokines and inflammatory factors 
that influence inflammation(54, 55).    
Neutrophils have three main functions: phagocytosis, degranulation, and release 
of nuclear material in neutrophil extracellular traps (NETs)(56). Within their granules are 
several types of proteins, including cytokines to recruit macrophages promote the 
neutrophil presence(57). Neutrophils from the blood are mobilized to sites of infection or 
inflammation through the leukocyte adhesion cascade(58, 59). When an injury occurs, 
chemoattractants called damage-associated molecular patterns (DAMPs) are released 
from dying cells to recruit circulating neutrophils. In addition, IL-1a and IL-33 are 
released from cells following necrotic cell death(60, 61). Following injury, endothelial 
cells close to the affected site are activated, and begin to express adhesion receptors, like 
E- and P-selectins(62). Neutrophils are able to bind these receptors, initiating their 
“rolling’ on the endothelium. The neutrophil is then activated by chemokines, which 
results in neutrophil adhesion to the endothelium(63). This allows for the neutrophil to 
then transmigrate into the nearby peripheral tissues, where they travel along 
chemoattractant gradients to elicit their response(64). These chemoattractants also signal 
to the surrounding tissues to increase immune cell chemotaxis. Examples of such signals 
are C-X-C motif chemokine ligand 8 (CXCL8) and leukotriene B4 (LTB4)(65).  
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Neutrophils responding to DAMPs can contribute to and perpetuate sterile tissue 
injury by the release of toxic effectors, such as reactive oxygen species (ROS)(66). 
Furthermore, the release of NETs can potentially injure the tissue, and has been attributed 
to the development of some diseases, such as systemic lupus erythematous (SLE), 
diabetes, and thrombosis(67).  NETs are made up of granular and cytosolic proteins, 
which could potentially present as autoantigens to host immunity(56, 68). This may 
signal for the additional release of DAMPs that may amplify the ongoing immune 
response. Thus, many strategies have been used to interfere with NETs before they can 
cause additional tissue damage(56). 
In the gastrointestinal tract, immune homeostasis is particularly important for 
maintenance of the epithelial barrier, which prevents antigens from permeating and 
causing an immune response. Normally, the intestinal epithelium is a physical barrier that 
presents contact between the luminal microbiota and intestinal mucosa. When the 
epithelial barrier is affected, increased intestinal permeability is increased, and persistent 
chronic inflammation can occur(42, 69). Neutrophils are then recruited to the infected site 
to phagocytose and kill pathogens through their many mechanisms of eradicating 
pathogens: phagocytosis, ROS, lytic enzymes from granules, and NETs(70). 
Recent studies have indicated that neutrophils play an important role in the 
pathogenesis of IBD, but depending on the experimental model utilized, it is unknown 
whether neutrophils have a beneficial or deleterious role. For example, depletion of anti-
neutrophil antibodies ameliorates colitis induced by dextran sulphate sodium (DSS) or 
trinitrobenzene (TNBS) in rats(71, 72). Other studies utilized a model of dysregulated 
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immunity, such as the T-cell transfer model, and found that neutrophils actually play the 
opposite role in UC pathogenesis.  
2.2.2 Macrophages are an important mediator between innate and adaptive immunity 
Macrophages exhibit a wide range of phenotypic heterogeneity and have a 
number of effector functions. Macrophages are involved in mediating communication 
between the innate and adaptive immune systems, killing pathogens and parasites, and 
promoting tissue repair(73). In response to tissue injury and during the wound healing 
cascade, macrophages secrete inflammatory cytokines, matrix degrading factors, and 
growth factors. However, once the inflammation begins to subside, these innate immune 
cells can become polarized to take on other fates for the promotion of healing. 
Macrophages exist on a spectrum from M1 “pro-inflammatory” to M2 “anti-
inflammatory” or “regenerative” macrophages(49). The heterogeneity of this cell type 
allows for the development of biomaterial-based therapies that can manipulate the 
inherent signalling and effector functions of macrophages. 
The presence of IFN γ, lipopolysaccharide (LPS), or TNF cause macrophages to 
take on an M1 phenotype. This subset of cells releases reactive oxygen species and 
inflammatory cytokines that promote an immune response, with the goal of ultimately 
clearing necrotic tissue and recruiting additional immune cell populations(49). These 
cells also secrete growth factors, including VEGF and FGF2(74). This is necessary for 
the normal healing response, but persistence of the M1 phenotype can lead to increased 
tissue damage and a perpetuating inflammatory response(75, 76).  
M2 macrophages can be polarized by signals such as IL-4, and IL-13. These cells 
support the deposition of ECM and promote wound closure via arginase-1 (CD206) 
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expression. This allows for the development and generation of collagen and FGF, and 
remodeling of the site of injury(77, 78). The dominant presence of M2 versus M1 
macrophages determines the activation status of the immune system, and whether a 
positive or negative healing outcome will occur(76). 
Indeed, macrophages have a crucial role in suppressing the neutrophilic response 
in autoimmune disorders, such as UC. Macrophages have been previously shown to play 
an important role in forming noncaseous epithelioid granulomas in the intestinal mucosa. 
These macrophages produce cytokines, such as TNF, interleukins (Il-6, 8), and others 
when activated, which signal to surrounding tissue and cells(79, 80).   
2.3 Role of the Adaptive Immune System 
Compared to innate immunity, the adaptive immune system provides a more 
specific, but delayed response. Adaptive immunity is regulated by T-cells and B-cells, 
whose cell surface receptors recognize specific “antigens” or molecular fragments of a 
pathogen presented to them by antigen-presenting cells (APCs). Typically, the innate 
immune system will process and present antigen to a T-cell specific for that antigen. 
Next, the innate cell binds to the naïve T-cell using “costimulatory” receptors(81, 82), 
which are expressed on innate cells after the pathogen is processed. Lastly, the innate cell 
will release signaling factors, or cytokines, that activate and condition a specific 
population of adaptive immune cell. This allows for T-cells to take on specific T effector 
fates (TEFF), which then have the important job of specifically eradicating the 
pathogen(83). 
During development, T-cell progenitors migrate from the bone marrow to the 
thymus. During this migration, the T-cells begin to express TCR, and once they reach the 
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medulla, they express either CD4 or CD8(84). CD4+ cells are known as T-helper cells 
(Th), and are differentiated into Th1, Th2, Treg, and Th17 subtypes, each with individual 
functions(85, 86). CD8+ T-cells, or cytotoxic T lymphocytes, are important for immune 
defense against viruses and bacteria, and play a role in tumor surveillance(87). In the 
event that the signaling factors from innate to adaptive immunity, or adaptive to adaptive 
immunity, are regulatory or anti-inflammatory, T-cells can take on an 
immunosuppressive fate(88, 89). Regulatory T-cells (TREGs) suppress the function of 
TEFFs and drive the immune system towards immune tolerance. This allows for the 
suppression of the immune response and return to homeostasis. Several types of Tregs 
have been identified, such as CD4+ cells, Th3 cells, Tr1 cells, and CD8+ Tregs(90-92).  
Adaptive immunity plays an important role in inflammatory disease, particularly 
in the case in IBD. Alteration in the proliferation of T-cell subsets may cause an increase 
in cytokines and signaling factors, leading to worsened disease(93). The gut-associated 
lymphoid tissue (GALT) is where antigens come into contact with effector CD4+ (Th1 
and Th2) and CD8+ T-cells(94). Tregs are capable of inhibiting other Th subtypes and 
have become a popular target for immunomodulatory biomaterials. Tregs are able to 
suppress autoimmune disease and can induce immunological tolerance(93). In fact, 
reductions in Tregs were found in colonic mucosa in IBD patients, suggesting an 
important role for Tregs in its pathogenesis(95).  
These studies suggest that Tregs are involved in suppressing the adaptive immune 
system, and potentially also reeling back the innate immune system. Tregs can do so by 
inhibiting neutrophil and macrophage activation and inducing macrophage polarization 
towards M2 phenotypes. There is therefore a complex interplay between innate and 
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adaptive immune systems in normal wound healing and in disease states. This complex 
signaling network can be manipulated and harnessed to direct tissue responses using a 
multifactorial approach.  
2.4 The interface between biomaterials and immunology 
 Biomaterials are defined engineered substances to interact with biological systems 
to either diagnose, treat, or elucidate mechanisms of disease. The first drug delivery 
system was described in the mid 1960s, when Folkman and Long introduced 
encapsulated anesthetic within silicone rubber into the myocardium of an animal to show 
control of the heart rhythm with release of the drug(96). The observation that small 
molecules could diffuse through polymers sparked the field of controlled-release 
technology. In the case of drug delivery, selection of the biomaterial is determined by its 
compatibility with the contained therapeutic(97). Further, the biomaterial must be able to 
be delivered in a manner that is translatable to patients and arrive at the organ system of 
interest. These systems aim to target a specific location for a short or extended period of 
time to achieve an effect. The method of delivery must be able to keep the enclosed 
therapeutic intact, and once the destination is reached, release drug in either a constant, 
oscillating, pulsating, or declining fashion(98).  For example, gastrointestinal delivery has 
proven challenging due to the acidity of the gastric system(99).  
 Notably, Folkman observed that the material induced inflammation after it was 
implanted into different tissues(100). As such, a main focus of biocompatible materials is 
to develop therapeutic materials that are compatible with biological systems, without 
causing immunogenicity. Recent work has focused on creation of novel materials with 
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the specific focus of harnessing and directing the power of immune system, without 
generating an undesired immune response.  
2.4.1 Novel molecular therapies for IBD 
 Treatment for IBD depends on the degree of severity and is different for patients 
with Crohn’s or UC. Current drug treatments aim to induce remission and ameliorate 
symptoms of disease. However, few therapeutics aim to modify or reverse the underlying 
causes of pathogenesis(101). Corticosteroids, aminosalicylates, and immunosuppressive 
agents are all involved in caring for patients with IBD(102). New approaches have used 
humanized monoclonal antibodies, such as antibodies against TNF or IL-6, which have 
become the standard of care(103). Because many pro-and anti-inflammatory cytokines 
are generated by the inflamed gut, TNF is a popular target. TNF inhibitors, like 
Infliximab, target the Th1 immune response of Crohn’s disease. Recent studies have 
suggested that infliximab may actually deplete some populations of intraepithelial 
inflammatory cells(104).  
 Though the development of more immune specific drugs and improved 
biotechnology has aided the development of novel medications, several challenges exist 
for therapeutic delivery to the gastrointestinal tract. Oral drug delivery would be the ideal 
mechanism of delivery. However, the absorption of oral drugs is complex. First, oral 
drugs must be soluble in gastric fluid for absorption into the stomach, small intestine, or 
large intestine(105). Furthermore, therapeutics must be able to withstand the low pH of 
the stomach, which ranges from 0.8-5(106). In addition, current therapeutics have a 
number of side effects, and preventing those side effects adds a layer of difficulty. 
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Potential side effects include nephrotoxicity, hepatotoxicity, peptic ulcers, infection, and 
even cancer(107, 108).  
 IBD treatment in particular necessitates a balance between therapeutic efficacy 
and reduced side effects. Potential strategies to increase therapeutic efficacy is by using 
particle carrier systems, which specifically release drug at the inflamed intestine(109). 
Because the intestinal barrier is disrupted, causing increased permeability(110, 111), 
alterations in mucus(112), and loss of epithelium(113), targeted drug delivery offer a 
range of therapeutic benefits, including preventing uptake by non-inflamed tissues, and 
the ability to deliver smaller doses, leading to reduced side effects. 
 Biomaterials research has focused on testing the biocompatibility of polymers and 
developing these materials as therapeutic agents. Hydrogels have been widely studied due 
to their ability to ability to form in the presence of cells and proteins, their ability to 
survive and thrive in biological environments(114), and their tunable physicochemical 
properties. For example, gelation of hydrogels can be induced by changes in pH(115), 
temperature, covalent or non-covalent bonding(116), or polymerization. Materials to 
form hydrogels can also be synthetic, such as poly(ethylene glycol) (PEG), 
poly(hydroxyethyl methacrylate) or naturally derived, such as collagen, hyaluronan, 
chitosan, or alginate(117). To design successful therapeutic materials, it is necessary to 
consider the interplay between the cellular environment and biomaterial. 
In the case of normal wounding and wound healing, or in chronic inflammatory 
disorders, biomaterials have played an important role in delivering therapeutic factors to 
either enhance the healing process or prevent further inflammation. Recent studies have 
shown that using materials such as silicone or hyaluronic acid, particularly high 
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molecular weight hyaluronan (HMWHA), alone, inhibit pro-inflammatory cytokines, 
such as IL-1β and TNF, and recruit factors that promote a healing response (118, 119). 
Other studies have attempted to use pre-devised therapeutic tools to augment or engineer 
the local microenvironment to mobilize reparative cell populations to exert their 
regenerative potential (120, 121). 
 In the case of chronic inflammatory disease in the gastrointestinal tract, 
therapeutic strategies have also focused on using biomaterials to suppress or ameliorate 
the overwhelming immune response to prevent local tissue damage. A recent study found 
that by functionalizing nanoparticles with poly(ethylene) glycol (PEG), particles were 
able to specifically translocate and deposit in inflamed tissues(109). Other potential 
strategies for drug delivery include liposomes(122), polysaccharide-based and PLA-
based nanoparticles(123), and NiMOS(124).   
 Liposomes have been conjugated with ligands on their surface to specifically bind 
the receptors of enterocytes. A recent study developed integrin B7 antibody-conjugated 
liposomes that specifically targeted leukocytes in colonic inflammation. Liposomes have 
also been used as a delivery vehicle for siRNA. Importantly, these liposomes are usually 
coated with mucoadhesive polymers, such as chitosan, to remain intact through the 
gastrointestinal tract(125).  
2.4.2 Polysaccharide-based materials 
One of the most attractive areas in research is designing nanosystems that can 
deliver drugs exactly to the site of inflammation, at the right dosage and in an appropriate 
time frame. Polysaccharide-based materials have the ability to improve and increase the 
duration of the therapy, and prevent drug degradation(126, 127).  These materials are 
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popular drug carriers, based on their biocompatibility, low toxicity, and low cost(128). 
Some polysaccharides, such as chitosan, alginate, and hyaluronic acid, have the potential 
for bio-adhesion by forming non-covalent bonds among functional groups and 
epithelium(129). Chitosan, for example, is a linear cationic polysaccharide derived from 
the deacetylation of chitin. Chitosan is often used as a mucosal delivery agent due to its 
ability to interact with anionic molecules or tissues(130).  
 Alginic acid is derived from Pseudomonas aeruginosa, whose biofilms consist of 
the  β-D-mannuronate and a-L-guluronate units, as well as the cell wall of brown 
algae(131). Alginate can form hydrogels under mild gelation conditions ideal for protein 
encapsulation. To enhance the hydrogel mechanical properties, a chitosan coating can be 
used to form a polyelectrolyte complex and prevent the leakage of encapsulated 
drug(132, 133). In low pH environments, chitosan amine groups become protonated, 
which strengthens the electrostatic properties of anionic alginate and cationic chitosan. At 
intestinal pH, alginate gels swell and the charge of chitosan reverses to negative(134, 
135). This swelling allows for the release of loaded drug. The encapsulation within 
alginate and chitosan also prevents the loaded cargo from enzymatic degradation(126).  
 Alginate and chitosan are two promising biodegradable polymers that already 
have widespread usage in the pharmaceutical industry(136, 137). Alginate cross-linking 
alone has low mechanical stability that results in quick release of drug, thus, alginate 
nanoparticles and microparticles can be coated with polycationic polymers, such as 
chitosan or poly-L-lysine, that increase mechanical integrity(138-140). Alginate/chitosan 
microparticles have been developed specifically for M-cell uptake in the gastrointestinal 
tract(138, 141). M-cells are specialized epithelial cells located in the Peyer’s patches, or 
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GALT. Alginate-gels have been extensively studied, as calcium ions have a specific 
interaction with G-units in alginate(142, 143).  When a polycation and polyanion are 
mixed when fully charged, they do not form a gel. The amino-groups on chitosan have 
pKa-values around 6.5, whereas the carboxyl-groups from alginate have pKa values at 3.5, 
indicating that between pH 4-6 is a strong ionic interaction between positively charged 
chitosans and negatively-charged alginate(142, 143). In order to take advantage of this, 
Laroui et al designed a hydrogel made of chitosan and alginate that was sensitive to the 
pH of the intestine and would collapse once arriving to that specific location. Within the 
hydrogel were nanoparticles (NPs) containing anti-inflammatory peptides. The ability to 
protect therapeutic NPs through the stomach for specific release in the small intestine 
allowed for lower drug doses to be delivered, and the study showed reduction of mucosal 
inflammation in a mouse model of colitis(144). This unique colon drug formulation, 
called the NP-in microparticle oral delivery (NiMOS) system has been previously used to 
deliver plasmid DNA in specific regions of the gastriointestinal tract(145). NiMOS 
systems combine the ability of nanoparticles to passively target inflamed tissue, whereas 
microparticles (MPs) provide an increased loading capacity for therapeutics (146, 147).  
 Another synthetic polymer that has been used for the delivery of therapeutics are 
PEG hydrogels. PEG-4MAL, in particular, has been used due to its ability to be 
functionalized with adhesive peptides and crosslinked to generate hydrogels(148). 
Poly(ethylene glycol) (PEG) is a non-toxic, non-immunogenic(149), water soluble 
polymer that has been approved for a wide range of biomedical applications. PEG 
polymers have high water solubility, favorable pharmacokinetics, and can be conjugated 
with biological molecules(150). In addition, the biocompatible properties of PEG gels are 
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extended to the conjugated substance, including protection against proteases and reduced 
clearance(151). PEG has been used to modify therapeutic proteins to increase their 
solubility, lower toxicity, and prolong their half-life(152). Polymeric materials can be 
modified via the formation of bonds (cross-linking) or bond breaking (controlled 
degradation/release)(153). Enzymatic degradation of hydrogels usually occurs in 
proximity to cells. Notably, sequence-specific degradation can occur by incorporating 
linkages sensitive to matrix metalloproteinase (MMP) degradation(154). For example, the 
target sequence GCRDVPMSMRGGDRCG (VPM) has been shown to be degraded by 
proteases such as MMP-1, MMP-2, and collagenase(155). Thus, it is thought to be a 
model peptide cross-linker for biological applications.  
 An advantage of using PEG gels is their ability to incorporate various reactive 
groups. Michael-type addition of 4- or 8-arm PEG macromers with acrylate, vinyl-
sulfone, and thiol end-groups have been studied(156). Maleimide (H2C2(CO)2NH) is a 
compound that is often linked to PEG chains to allow for the linking of proteins to the 
polymer surface. Maleimides have fast reaction kinetics and high specificity towards 
cysteines at physiological pH, making them desirable for the development and 
preparation of targeted therapeutics(157). Importantly, 4-arm PEG-MAL hydrogels 
exhibit improved cross-linking efficiency, bioligand incorporation, and reaction time 
scales that can be translatable into the clinic(158). Thus, PEG-4MAL is another 
biomaterial that may be useful in delivering therapeutics and modulating and directing 
the immune response. 
2.5 Using dimensionality reduction techniques to elucidate cellular heterogeneity in 
data 
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Techniques that measure single-cell data can offer precise measures of cellular 
components and activation profiles representing important functions in biology. Variation 
of biochemical functions in complex cell populations can be used to extract unique 
insights into the underlying cellular signaling relationships(159). Flow cytometry is a 
powerful tool that provides multi-parametric single-cell data of a heterogeneous 
population of cells(160). This single-cell data allows for quantification of cellular 
heterogeneity(161, 162), identification of rare cells(87, 163), and analysis and correlation 
of single-cell features with clinical pathologies(164, 165). Analysis using flow cytometry 
has becoming increasingly complex, as rapid development of new markers and 
measurements have grown beyond the ability of conventional manual gating 
analysis(166, 167). Currently, single-cell flow cytometers provide measurements of up to 
12 fluorescent parameters, with the ability to include up to 17 protein parameters(160).  
In order to adequately analyze this multi-faceted data, it is necessary to have a well-
thought out panel, proper controls, and a well-supported gating strategy. With the 
development of new techniques, such as mass cytometry and new techniques in flow 
cytometry, more parameters can be tested for than ever before. In fact, mass cytometry 
allows for the collection of 30-38 antibodies worth of information, providing both 
intracellular and extracellular information(168).  
A major challenge when collecting so much information is deciphering methods to 
analyze the data. This involves the challenge of elucidating the contribution of each cell 
to the overall network of information, while minimizing noise and contamination. 
Importantly, analyzing flow data is subject to quite a bit of bias, and require detailed 
knowledge of underlying cellular phenotypes. In particular, “gating” of cell populations 
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is where the researcher selects subsets of cells defined in a biaxial plot of two 
measurements to calculate a desired phenotype(166). Clustering algorithms have been 
developed to deal with such data, using unsupervised learning techniques to identify rare 
cell populations and characterize cell populations across samples(169). Automatic gating 
algorithms capture abundant cell types at the expense of rare cell types, who are either 
lost or absorbed into nearby clusters. Due to the high-dimensional nature of multi-color 
data, novel data analysis tools have been developed to deal with the complex nature of 
the information obtained, such as SPADE(162) and tSNE(170). These tools derive low-
dimensional (2D or 3D) visualizations of that preserve the high-dimensional structure of 
the dataset.  
 Spanning-tree Progression Analysis of Density-normalized Events (SPADE) is a 
computational technique that was developed to create a 2D visualization of multiple 
populations of cells in a branched “tree”(171). This tree is constructed without much 
needed oversight from the user. SPADE separates acquired data from flow cytometry and 
mass cytometry into hierarchically organized clusters that reflect all of the dimensionality 
in the data(162). Biaxial plots on software such as FlowJo requires the drawing of gates, 
from which cellular phenotypes can be determined. Instead, SPADE uses topological 
methods to create geometrical shapes from which clouds of cells are clustered.  
 SPADE works in four steps(171). First, data is down sampled in a density-
dependent manner to normalize the of cellular data. Each cell is identified as a point with 
multi-dimensions (i.e. the number of cellular markers). Since denser regions represent 
abundant cell phenotypes, this allows for rare cell types to be equally weighted as 
abundant cell types. The second step is agglomerative clustering to separate down 
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sampled data into cell clusters, so that they associate with cells with similar marker 
makeup. Agglomerative clustering is a bottom-up technique for which each point of data 
is in 2D space. Each point is a singleton cluster that goes through many iterations to find 
a pair of clusters that is closest. Clustering iterations continue until the number of clusters 
reaches an amount specified by the user. The output is a dendrogram, a hierarchical 
structure, or tree, of clusters. In order to simplify the data, the distance threshold can be 
set such that every node becomes associated into a cluster. This number of clusters, or 
nodes, can be modified by techniques such as X-Shift, which uses relative densities to 
generate centroids(172). The remaining data sets are connected to centroids forming 
clusters. This algorithm can calculate the number of clusters that can be specified on 
SPADE in order to obtain unique density-separated populations(173). 
 Next, SPADE performs minimum spanning tree construction for extraction and 
creating a summary of the geometry of the cloud(162). This is done by using an 
algorithm to that links the cell clusters. Lastly, SPADE upsamples the data to map each 
cell in the dataset to the most similar cluster. Each cell cluster is one node of the tree, and 
the color of the nodes represents the median intensities of protein markers. This allows 
for a 2D visualization of how the markers interact, and a thorough analysis of 
heterogeneity of the diverse cell population. SPADE deals with high-dimensional 
datasets by using Fruchterman and Reingold algorithms for construction of the tree(174). 
This means that the creation of the SPADE tree aligns nodes along the longest path of the 
tree, followed by gradually appending the rest of the nodes to the main arch.  
 There are many benefits to using SPADE to analyze large datasets. First, an 
objectively derived topology allows for less subjectivity than gating strategies on FlowJo. 
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Instead of viewing data in a 2D biaxial plot, SPADE allows for a multidimensional view 
of cellular phenotypes and expression profiles. In addition, this multidimensional dataset 
can be uniquely used to identify changes in dimensionality, including differentiation or 
subtle changes in marker expression as cells transition between phenotypes(163, 165, 
171).  
 There exist some drawbacks to methods like SPADE, however. For example, if 
many experiments were performed that used different fluorophore-tagged antibodies, it 
becomes challenging to organize and make conclusions based on the data. In addition, 
identifying phenotypes when there are multiple markers required can be difficult, 
especially in cases where cells may be in a transition period or marker expression is 
changing. To solve this problem, using unsupervised hierarchical clustering methods, 
such as the creation of heatmaps, can allow for the visualization of marker expression in 
each node as determined by SPADE at one time. The utilization of a heatmap can be a 
faster and easier way to organize the median marker expression to quickly identify cell 
phenotypes of nodes.  
 SPADE allows for the exploration of high-dimensional datasets in an objective 
manner. Importantly, SPADE allows for the identification of trends in cellular 
heterogeneity, as well as the elucidation of rare cell events that may not have been even 
considered by manual gating. Here, we use SPADE to characterize the immune response 
to immunomodulatory biomaterials in the context of wound healing and in the 
gastrointestinal system. These studies highlight the role of dimensionality reduction 




CHAPTER 3. DUAL DELIVERY OF IL-10 AND AT-RVD1 FROM 
RGD-FUNCTIONALIZED PEG HYDROGELS POLARIZE 
IMMUNE CELLS TOWARDS PRO-REGENERATIVE 
PHENOTYPES 
3.1 Introduction 
The immune response to injury is a complex process that involves the orchestration of 
many different cell populations in coordination to restore tissue homeostasis. In healthy 
individuals, tissue regeneration can occur without much intervention. However, in the case of 
disease states, or in wound healing following surgical procedures, the immune response to 
healing can become dysregulated, and prevent restoration of normal tissue(1, 175, 176). 
Identification of the key factors required to achieve tissue regeneration has remained elusive, 
especially in the context of large wounds or transplanted tissues. This can lead to wound closure 
failure, or a chronic inflammatory state. The involvement of immune cells is required for aspects 
of development beyond initial inflammation. It has been shown that the specific immune response 
and the profile of immune cells recruited to the site of injury can determine wound repair 
quality(177).  
Immediately following injury is a cascade of inflammatory signaling that recruits local and 
blood-derived leukocytes to the wound or transplant site(178). Innate immune cells, cytokines, 
and lipid mediators have classically been shown to play an early role in directing repair and 
influencing the immune microenvironment. For example, resolvins are a class of bioactive small 
molecule lipids that come from the omega-3 polyunsaturated fatty acids eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA)(179). These lipid mediators act to drive the resolution of 
inflammation. The “D-series” of resolvins act as endogenous agonists of GPR/32 and ALX/FPR2, 
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which are expressed broadly throughout immune cells, including lymphocytes, and specialized 
epithelial cells. AT-RvD1 is part of a class of “specialized proresolving mediators” (SPMs) 
capable of redirecting the immune response towards resolution and healing. This signaling as a 
response to injury next effects endothelial cells, which respond to and amplify the signals(180). 
We have previously utilized Aspirin-Triggered Resolvin D1 (AT-RvD1) to increase the 
recruitment of anti-inflammatory monocytes and M2 macrophages to an injury site(181).  
Macrophages are innate immune cells that play an important role in organ development, 
host defense, tissue homeostasis, inflammation, and remodeling(182). Their ability to sense and 
respond to a number of stimuli, combat foreign pathogens, and maintain tissue integrity depicts 
the unique, yet complex, role they play in immunity. Macrophages are thought to take on a 
spectrum of roles, spanning from pro-inflammatory to anti-inflammatory. These fates span from 
naïve (Mo), to classically activated (M1) macrophages containing pro-inflammatory processes, to 
alternatively activated macrophages (M2), which have anti-inflammatory activity(183).  
M1 macrophages are induced by intracellular pathogens and inflammatory cytokines, 
including IFN- 𝞬 and TNF-𝛼, and are characterized by pro-inflammatory cytokine production, 
such as IL-1B, IL-6, and IL-12(3). The primary function of this subtype is to remove foreign 
pathogens and tumor cells. M2 anti-inflammatory macrophages are identified by expression of 
the CD206 mannose receptor in addition to MerTK and CD64(78). M2 macrophages have 
enhanced phagocytosis abilities, can produce extracellular matrix (ECM) and angiogenic factors, 
and secrete interleukin 10 (IL-10), a cytokine that plays a critical role in the dampening of 
immune responses following inflammation.(184) These qualities of IL-10 make it an attractive 
agent for the promotion of wound healing due to its ability to direct anti-inflammatory effector 
functions immune cell subsets. Both subsets of macrophages are critical for proper wound 
healing(185). M1 macrophages remove debris, damaged matrix, and dead cells. Further, they 
secrete factors such as fibroblast growth factor (FGF) and VEGF that recruit immune cells. The 
development of new tissue cues the transition from macrophages into the anti-inflammatory state, 
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which can then secrete anti-inflammatory cytokines, promoting ECM formation and tissue 
contraction, and initiating the resolution of inflammation and peripheral tolerance(5, 78).  
Peripheral tolerance is the process that prevents immune cells from initiating dangerous 
responses against the body’s own tissues. In the context of large injuries or organ transplant, 
failure of this process can result in dysregulated healing and transplant rejection. This careful 
balance is mediated by cells from the innate and adaptive immune system, which ensure that the 
proper signals dictate a pro-inflammatory or anti-inflammatory state(186). Early pro-
inflammatory signals and innate cell responses are critical factors in establishing the 
inflammatory microenvironment. Immature dendritic cells (DCs) express a number of 
chemokines that are associated with inflammation. Notably, DCs are responsible for detecting 
and capturing foreign antigen and presenting those antigens to T lymphocytes to induce their 
actions(187). DCs are also involved in the balance in stimulating the adaptive immune response. 
In particular, tolerogenic DCs (tolDCs) are involved in communicating the switch to anti-
inflammatory phenotypes, and the induction of T-cell polarization towards T-regulatory cells 
(Treg) via the secretion of cytokines, such as IL-10(188). Interleukin 10 (IL-10) is a cytokine that 
is expressed by both innate and adaptive immune cells, and plays a critical role in the control of 
immune response(189). IL-10-producing DCs can induce functional Tregs, which has been 
shown to reduce the Th17 inflammatory response. Moreover, IL-10 plays an essential role in 
regulating scar formation during wound healing, reducing scar formation after injury(190). This 
balance is facilitated by the local micro-environment and the presence of pro- or anti-
inflammatory cytokines. Tolerogenic DCs promote resolution of ongoing immune responses and 
prevention of autoimmunity by generating Tregs and limiting effector T cell differentiation(191, 
192). DCs that induce Tregs are characterized by cytokines such as TGF-β and IL-10. Common 
surface molecules and cytokines used as markers for Tregs are CD25 and IL-10(193). Currently, 
the balance of effector/regulatory T-cell and M1/M2 macrophages is thought to determine the 
degree of inflammation or repair(194).  
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In order to achieve this balance and modulate infiltrating immune cell populations to 
stimulate repair, we developed a “pro-regenerative” hydrogel via the delivery of AT-RvD1 and 
IL-10 to specifically recruit and polarize immune cells with anti-inflammatory properties. We 
have previously shown the utility of AT-RvD1 using a degradable biomaterial to increase the 
recruitment of anti-inflammatory monocytes and M2 macrophages. AT-RvD1 is part of a class of 
“specialized proresolving mediators” (SPMs) capable of redirecting the immune response towards 
resolution and healing. There is thus a important role for AT-RvD1 delivery for the enhancement 
of wound healing(181). By delivering AT-RvD1 with IL-10, we hypothesize that we can 
manipulate immune cells to polarize towards anti-inflammatory fates, resulting in recruitment of 
M2 macrophages, IL-10 expressing DCs, and Tregs. In this study, we show that two bioactive 
factors, AT-RvD1 and IL-10, are capable of eliciting a synergistic healing response. Using the 
murine dorsal skinfold window chamber as a test bed to measure the response to 
immunomodulatory hydrogels, we demonstrate that not only is the recruitment of anti-
inflammatory myeloid cells enhanced by AT-RvD1 delivery, but combination IL-10+ATRvD1 
treatment is able to concurrently increase populations of macrophages, dendritic cells, and T cells 
involved in wound healing. These results indicate that dual delivery of IL-10 and AT-RvD1 has 
broad effects on the recruitment of pro-regenerative, anti-inflammatory innate and adaptive 
immune cells and can result in the modulation of the immune response after injury to promote 
tissue regeneration and healing. 
3.2 Results 
3.2.1 Engineering immunomodulatory hydrogels to promote resolution and immune polarization 
A strategy for the promotion of resolution is to modulate the immune profile involved in 
the inflammatory cascade. In order to modulate the immune response, we identified two factors 
that play different roles in the inflammatory response, AT-RvD1 and IL-10. AT-RvD1 is 
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involved in the resolution phase of inflammation, and IL-10 is involved in the polarization phase, 
influencing the polarization of pro-inflammatory cells to anti-inflammatory cells. In order to 
increase the half-life of both factors at the site of injury, both were packaged individually or 
combined into hydrogels for delivery. Here, we used gels formulated by poly(ethylene glycol) 
(PEG) hydrogels using 10kDa 4-arm PEG macromers containing terminal maleimide groups 
(PEG-MAL). The cysteine-flanked peptide GCRDVPMSMRGGDRCG (VPM) that contains a 
protease cleavage site was used to crosslink the PEG-MAL macromers. We expected that 
protease cleavage of the gels would cause burst release of AT-RvD1, which would promote 
wound resolution, followed by slow-release of IL-10, which would cause the recruitment and 
polarization of anti-inflammatory cell subtypes (Figure 1A,B). 
We first loaded fluorescently-tagged human IL-10 into a hydrogel and measured its 
release. Within the first 30 minutes, 58.24±0.67 ng was released, followed by 175±1.34ng after 2 
hours, and 209.62±1.73ng after 6 hours. At 24 hours, the gel released 227.40±1.71ng of the 
loaded IL-10, which was over 90% of the initial dose. By day 5, 235±1.73ng total IL-10 was 
released, and only 22.39±4.85ng (Figure 1C) was recovered from the digested gel. To test 
whether we could achieve gradual release of IL-10, we then attempted to functionalize the IL-10 
with free cysteines to allow for interaction with the PEG-MAL macromer. The macromers 
containing terminal maleimide groups on PEG gels are able to react with free cysteines on 
peptides or full-length proteins. Since human IL-10 does not have a free cysteine in its structure, 
and we used Traut’s reagent (2-iminothiolane) to thiolate the IL-10. This reagent reacts with 
primary amines to form sulfhydryl groups. This resulted in about 3 free cysteine groups per IL-10 
molecule. In contrast to the unmodified IL-10, thiolated IL-10 releases 7.67 ± 2.76 ng after 30 
minutes, 26.91 ± 2.91 ng at 2 hours, 32.39 ± 2.67ng at 6 hours, and 42.03 ± 2.45ng by 24 hours. 
The thiolated IL-10 released gradually with a measured release of 73.28 ± 3.55ng at 5 days, with 
176.72 ± 5.42 ng remaining IL-10 that recovered from the gel after digestion. These data suggest 
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that thiolation of IL-10 greatly affects release kinetics and allows a more gradual release of 
therapeutic payload. 
We also measured the release of AT-RvD1 and observed that it was released in a manner 
similar to unmodified IL-10, with 87.66±1.29ng released by 24 hours. By day 5, only an 
additional 4ng had been released, with total release around 91.24 ±1.11ng (Figure 1D). When the 
release was measured from dual-loaded gels, there was no effect on the release kinetics of either 



























Figure 1. Hydrogel synthesis. 
(A) Schematic of hydrogel formulation containing IL-10 and AT-RvD1 (B) Composition of 
the hydrogel. (C) Release of unthiolated and thiolated IL-10 from 10kDA PEG-MAL 
hydrogels over the course of 5 days. (D) Release of AT-RvD1 from 10kDA PEG-MAL 
hydrogels over the course of 5 days.  
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3.2.2 Anti-inflammatory macrophages and dendritic cells accumulate after local 
immunomodulatory hydrogel delivery 
After profiling the recruitment of circulating immune cell subsets in response to 
immunomodulatory hydrogels, we extended our analysis to specific macrophage subpopulations. 
We examined dynamic changes in macrophages at days 1, 3, and 7 after tissue injury and 
implantation of PEG-MAL hydrogels. Expansion of macrophage populations is a hallmark of the 
resolution of inflammation and is necessary for tissue regeneration and wound healing (195). We 
then used flow cytometry to identify specific macrophage subpopulations present in the tissues 
over time. Macrophages are identifiable with flow cytometry by their surface receptor expression 
of MerTK and CD64(196). 
Macrophages were subclassified into M1 and M2 phenotypes as previously described 
(197). M1 “classically activated” macrophages were characterized by their expression of the 
costimulatory molecule CD86 and did not express the mannose receptor CD206. Temporally, we 
observed an increase in the M1 population at day 3 when they comprised on average 15% of the 
total macrophage population. The M1 population decreased by day 7 and was significantly 
decreased after AT-RvD1 or combination IL-10+AT-RvD1 treatment compared to control 
(Figure 2A). Conversely, M2 alternatively activated macrophages were characterized as CD86-
CD206+. At day 1, these macrophages made up a higher proportion of the total macrophage 
population, possibly due to pre-existing populations of tissue resident macrophages that express 
CD206(198). We observed significant increases in the M2 macrophage population at 24 hours in 
the AT-RvD1-treated and IL-10+AT-RvD1 treated animals compared to internal control. At days 
3 and 7 the average proportion of M2 macrophages had increased compared to the previous 
timepoint but did not change between IL-10 treated tissue and internal control. We saw 
significant increases in the M2 population after AT-RvD1 and dual delivery of IL-10 and AT-
RvD1 compared to control at days 3 and 7 (Figure 2B). This accumulation of M2 macrophages 
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occurred at a faster rate with dual delivery hydrogels, as the population of M2 macrophages was 
significantly increased in IL-10+AT-RvD1 treated animals compared to AT-RvD1-only delivery 
at day 3, indicating a modulation in recruitment or differentiation kinetics driven by co-delivery 
of these two factors. 
Given the increasing knowledge of the roles immune system and plays in promoting 
wound healing and tissue regeneration, we quantified the temporal response of dendritic cells to 
immunomodulatory PEG-MAL hydrogels. Dendritic cells have been shown to play previously 
unknown roles in the wound healing cascade, and specifically the CD11c+ IL-10+ tolerogenic or 
regulatory subset has been shown to enhance left ventricle function and remodeling following 
acute myocardial infarction and is able to stimulate the proliferation of Tregs(199, 200). Like 
monocytes and macrophages, dendritic cells are able to carry out pro- and anti-inflammatory 
effector functions, and pathologic dendritic cell activation leading to increased inflammatory 
cytokine production and stimulation of the adaptive immune system has been associated with 
chronic inflammatory disorders such as systemic lupus erythematosus and rheumatoid arthritis 
(201). In our mouse model, we observed recruitment of IL-10+ dendritic cells after one week 
across all groups and found that IL-10+DCs were significantly increased in combination IL-
10+AT-RvD1 treatment compared to IL-10 only and AT-RvD1 only treatments (Figure 2C). 
Consistent with our hypothesis that IL-10 and AT-RvD1 delivery are able to reduce the activation 
of pro-inflammatory pathways, we observe decreased intracellular TNF-α expression in CD11c+ 
dendritic cells at day 3 in the IL-10 and IL-10+AT-RvD1 hydrogel treatment groups, and reduced 













































Figure 2. Anti-inflammatory macrophages and dendritic cells accumulate after local 
immunomodulatory hydrogel delivery.  
 
Flow cytometric analysis of macrophages, (A) CD86+ M1 macrophage and (B) CD206+, 
and dendritic cell IL-10 (C) and TNF (D) expression in the dorsal skinfold window chamber 
following treatment with immunomodulatory PEG-MAL hydrogels. Open circles correspond 
to unloaded internal control; closed circles are treated tissue. Statistical analysis was 
performed using two-way repeated measures ANOVA with Tukey’s or Bonferroni post-hoc 
test. Data presented as internal control and treatment with connecting lines. *p<0.05, 
**p<0.01 compared to internal control, ^p<0.05, ^^p<0.01, ^^^p<0.001 compared to other 
treatment group, n=4. 
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3.2.3 Dimensionality reduction analysis reveals trends in innate immune cell heterogeneity by 
day 7 
Flow cytometry and IMARIS imaging (not shown) identified increased populations of 
pro-regenerative innate immune cells, such as M2 macrophages and IL-10+ DCs. Thus, we 
created an array of SPADE dendrograms to elucidate trends in cellular heterogeneity by day 7. 
We created SPADE representations using CD11b+ cells as indicative of myeloid cells, and then 
used MerTK+ CD64+ markers to create a “base” SPADE dendrogram representative of 
macrophages that express those markers (Figure 3A). By overlaying individual immune cell 
markers, such as CD86 or CD206, onto this base SPADE dendrogram, we were able to identify 
nodes that were specific for CD86+ cells, which indicated an M1 phenotype (Figure 3B), or 
CD206+, indicating an M2 phenotype (Figure 3D). We only identified 3 M1 nodes by day 7, but 
were able to identify 21 M2 nodes, indicating the prevalence of pro-regenerative phenotypes one 
week after treatment. We then created tornado plots to indicate the pseudotime trajectory of cell 
frequencies in each node. This analysis shows that, in IL-10, when comparing the treatment group 
against the control, there does not seem to be a shift in M1 macrophage cellular heterogeneity 
(Figure 3C). However, in the AT-RvD1 treatment, group, there is a shift in control cells towards 
an M1 phenotype in the remaining nodes by day 7. Additionally, in the dual IL-10+AT-RvD1 
group, the M1 macrophages skew strongly towards the control group over treatment. 
  In M2 macrophage dominated nodes, in IL-10 alone and AT-RvD1 alone, there was no 
clear trend when comparing control nodes against treatment nodes. However, in the dual hydrogel 
group, there is a robust shift in multiple nodes towards treatment, indicating the immune 
microenvironment transitioning towards a pro-regenerative phenotype by day 7 (Figure 3E).  
 
3.2.4 Characterization of Dendritic Cell Recruitment Dynamics using SPADE 
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Given the increasing knowledge of DCS and tolDCs in wound healing and tissue 
regeneration, we wanted to validate the observed temporal response of DCs to IL-10+AT-RvD1 
hydrogels in the dorsal skinfold window chamber model. Flow cytometry revealed decreased 
intracellular TNF expression in CD11c+ DCs at day 3 in IL-10 alone and IL-10+AT-RvD1 
groups, and reduced TNF in all groups compared to control in day 7. In addition, significant 
increase in IL-10 expression was observed by day 7 in all groups compared to internal control. 
Notably, IL-10+ alone and IL-10+AT-RvD1 had the highest increases in IL-10+ DCs. 
We thus decided to investigate the trends in DC IL-10 expression via SPADE. Thus, we 
developed a CD11c+ “base” tree to incorporate all positive cells. ( 
 
 




Figure 4B). This resulted in the identification of 22 IL-10+ CD11c+ nodes. However, when we 
created tornado plots to identify cell frequency differences in IL-10+ DCs, we do not see clear 
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trends in either IL-10 alone or dual hydrogel groups. However, we did observe a clear shift in the 









Figure 3. Trends in macrophage heterogeneity in response to immunomodulatory hydrogels.  
SPADE trees were developed to identify trends in macrophage heterogeneity. A base macrophage 
tree was created after gating for CD11b+ MerTK+ CD64+ cells (A). SPADE analysis indicates 
nodes positive for CD86+ M1 macrophages (B) and CD206+ M2 macrophages (D). Tornado plots 
were used to identify shifts in cell frequency after IL-10 alone, AT-RvD1 alone, and dual delivery 
compared to internal control (C, E). Difference in cell frequency was calculated by subtracting 






Figure 4 Trends in dendritic cell heterogeneity in response to immunomodulatory hydrogels.  
SPADE trees were developed to identify trends in intracellular expression of IL-10 in dendritic 
cells. (A) A base dendritic cell tree was created after gating for CD11c+ cells. (B) SPADE analysis 
indicates nodes positive for IL-10 expression (C). Tornado plots were used to identify shifts in cell 
frequency after IL-10 alone, AT-RvD1 alone, and dual delivery compared to internal control. 







3.2.5 T-cell recruitment dynamics in the dorsal tissue 
Flow cytometry and imaging studies (not shown) identified increased populations of 
CD206+ macrophages and IL-10 co-expressing dendritic cells (DCs), with reduction in pro-
inflammatory macrophages subtypes. Thus, we hypothesized that the immunomodulatory effects 
of our hydrogel treatment would likely modulate the adaptive immune system. DCs, for example, 
have become recognized for their regulation of both innate and adaptive immunity. In particular, 
DCs have recently been shown to ensure “immunological peace”(192). As tissue-resident DCs 
mature, they acquire T-cell stimulatory capacity and are able to convert conventional naïve T 
cells to a Treg phenotype or promote Treg function(202). These “repair” Tregs can be either 
CD4+ or CD8+, and have been suggested to promote wound healing and repair in multiple 
tissues(203).  
Thus, we performed flow cytometry on isolated tissue from the window chamber, adding 
CD3+, CD4+, CD25+, and CD8+ markers for adaptive immunity. Because of the increase in IL-
10+ dendritic cells, we aimed to identify adaptive immune populations from a base CD3+ 
SPADE dendrogram (Figure 5A). We first identified CD4+ CD25+ T-regulatory cells using 
SPADE by creating a CD3+ CD4+ tree (Figure 5B), and then a CD3+ CD4+ CD25+ tree 
(Figure 5C). From this, we were able to identify 30 nodes that were positive for both CD4 and 
CD25. We then plotted the difference in cell frequency in the treatment from control samples to 
identify shifts in cellular heterogeneity (Figure 5D). In accordance with the trends in CD11c+ 
IL-10+ SPADE nodes, the AT-RvD1 alone group was the only treatment group that showed a 
slight trend towards treatment in CD4+ CD25+ cells over control. However, we did not observe 
other trends in either the IL-10+ or dual IL-10+AT-RvD1 groups. 
3.2.6 SPADE analysis reveals trends towards unexpected pro-regenerative adaptive immune cell 
population at day 7 following dual treatment with IL-10+AT-RvD1  
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For a thorough investigation into the involvement of the adaptive immune system, we 
also developed SPADE trees for CD8+ T-cells. Following the creation of a CD3+ base SPADE 
tree (Figure 6A), we then identified CD8+ cells using SPADE by creating a CD3+ CD8+ tree 
(Figure 6B). Interestingly, while creating the tree, we noticed a subpopulation of nodes that had 
concurrent IL-10 expression. We thus created a third tree with CD3+ CD8+ IL-10+ nodes 
(Figure 6C). We then plotted the difference in cell frequency in the treatment from control 
samples to identify shifts in cellular heterogeneity (Figure 6D). This analysis revealed the 
presence of a CD8+ IL-10+ subpopulation of cells that were unexpected. This CD8+ IL-10+ co-
expressing cell only seems to be robustly increased in the treatment group in the dual IL-10+AT-
RvD1 group, suggesting a potential interplay between the delivered therapeutics that caused the 
recruitment of this rare immune cell population. These data suggest a unique role for the adaptive 
immune system in response to biomaterials at the injury site. Moreover, these data show the 
importance of using advanced computational methods to elucidate multidimensional cellular data 





Figure 5. Adaptive immune response to immunomodulatory hydrogels.  
SPADE trees were developed following flow cytometric analysis to identify adaptive 
immune cell subsets. (A) CD3+ base trees were developed after gating for CD3+ cells. 
SPADE analysis indicates nodes positive for CD4+ cells (B) and CD25+ (C) cells. Tornado 
plots were utilized to identify trends in cell frequency after IL-10 alone, AT-RvD1 alone, 
and dual delivery (D). 
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Figure 6 SPADE trees were developed following flow cytometric analysis to identify rare cell 
subsets.  
(A) CD3+ base trees were developed after gating for CD3+ cells. SPADE analysis 
indicates nodes positive for CD8+ cells (B) and IL-10+ (C) expression. Tornado plots 
were utilized to identify trends in cell frequency after IL-10 alone, AT-RvD1 alone, and 




The use of biomaterial implants to deliver cells or bioactive molecules capable of directing 
the host immune response after injury can modulate processes critical to the restoration of tissue 
homeostasis, such as cellular cytokine release, vascular remodeling, or deposition of extracellular 
matrix(175). It is becoming increasingly apparent that these processes are regulated not only by 
cells of the innate immune system, such as monocytes and macrophages, but that cells of the 
adaptive immune system play active and important roles. It is our goal to develop a material that 
can enrich the wound microenvironment with anti-inflammatory cells of both the innate and 
adaptive immune system to enhance the regenerative response.  
To attain a higher level of control over both innate and adaptive immune cell recruitment, 
we have developed a PEG-4MAL RGD hydrogel-based system capable of the dual delivery of 
two factors crucial for the recruitment and activation of pro-regenerative cells of both the myeloid 
and lymphoid lineages. Integrin signaling appears to play different roles in leukocyte migration, 
depending on the environment in which the cell is migrating. For example, monocytes utilize the 
integrin LFA-1 to crawl along the endothelium and extravasate into the tissue (204, 205). 
Conversely, leukocyte migration through interstitial space is not integrin-dependent and instead 
involves amoeboid-like flowing and squeezing motions (205). The critical parameter appears to 
be whether the cell comes in contact with a 2D barrier, such as the endothelium. Biomaterials 
provide a unique context to migrating cells, where the surface serves as a 2D barrier, but 
materials that are porous or have topographical features may be interpreted by cells as an 
analogous environment to interstitial space. These hydrogels were engineered with RGD to 
achieve in vivo recruitment of cells to the gel, following which degradation of the gel would 
result in AT-RvD1 and IL-10 release. In fact, we observed recruitment of macrophages, DCs, and 
adaptive immune cell populations. 
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Macrophages are identifiable with flow cytometry by their surface receptor expression of 
MerTK and CD64(196). Expansion of macrophage populations is a hallmark of the resolution of 
inflammation and is necessary for tissue regeneration and wound healing (195). We used flow 
cytometry to identify specific macrophage subpopulations present in the tissues over time.  
Macrophages were subclassified into M1 and M2 phenotypes as previously described (197). M1 
classically activated macrophages were characterized by their expression of the costimulatory 
molecule CD86 and did not express the mannose receptor CD206. Temporally, we observed an 
increase in the M1 population at day 3, followed by a decrease by day 7, particularly after AT-
RvD1 or combination IL-10+AT-RvD1 treatment compared to control. Conversely, M2 
alternatively activated macrophages were characterized as CD86-CD206+. At day 1, these 
macrophages made up a higher proportion of the total macrophage population, possibly due to 
pre-existing populations of tissue resident macrophages that express CD206(198). We saw 
significant increases in the M2 population after AT-RvD1 and dual delivery of IL-10 and AT-
RvD1 compared to control at days 3 and 7. This accumulation of M2 macrophages occurred at a 
faster rate with dual delivery hydrogels, as the population of M2 macrophages was significantly 
increased in IL-10+AT-RvD1 treated animals compared to AT-RvD1-only delivery at day 3, 
indicating a modulation in recruitment or differentiation kinetics driven by co-delivery of these 
two factors. 
Because we used 10 different markers to elucidate the roles of 6-7 cell types, we decided 
to use dimensionality reduction techniques to confirm our flow cytometry findings. Thus, we 
used SPADE to highlight novel aspects of immune alterations developed after 
immunomodulatory hydrogel treatment. SPADE is a dimensionality reduction technique that 
hierarchically clusters phenotypically similar cells into “nodes”. These nodes and their 
relationships are organized into a minimum spanning tree, or “SPADE tree”. To test this, we 
created SPADE trees of the individual macrophage populations of which we were interested. In 
accordance with the results from flow cytometry and intravital imaging (not shown), we observed 
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a shift in cellular heterogeneity towards the M2 anti-inflammatory macrophage phenotypes, and 
away from the M1 pro-inflammatory macrophage subtype, particularly in the dual hydrogel group 
when compared to internal control.  
Given the increasing roles of the immune system in promoting wound healing and tissue 
regeneration, we also quantified the temporal response of dendritic cells to immunomodulatory 
PEG-MAL hydrogels. Dendritic cells have been shown to play previously unknown roles in the 
wound healing cascade, and specifically the CD11c+ IL-10+ tolerogenic or regulatory subset has 
been shown to enhance left ventricle function and remodeling following acute myocardial 
infarction and is able to stimulate the proliferation of Tregs(27, 28). Like monocytes and 
macrophages, dendritic cells are able to carry out pro- and anti-inflammatory effector functions, 
and pathologic dendritic cell activation leading to increased inflammatory cytokine production 
and stimulation of the adaptive immune system has been associated with chronic inflammatory 
disorders such as systemic lupus erythematosus and rheumatoid arthritis (29). DCs have become 
recognized for their regulation of both innate and adaptive immunity. In particular, DCs have 
recently been shown to ensure “immunological peace”(192). On flow cytometry, we observed 
increased in IL-10+ tolDCs in in all groups, and reductions in TNF intracellular expression by 
day 7.  Interestingly, however, we did not observe the same trends after creating CD11c+ IL-10+ 
SPADE trees. The SPADE trees revealed an increase in IL-10+ DCs only in AT-RvD1 alone. If 
we look at the IL-10+ expression on the CD11c+ SPADE tree, it can be noticed that the nodes 
separate into 5 separate clusters. Thus, it may be possible that each cluster may be originating 
from a very heterogeneous DC population, and by simply gating out IL-10+ cells in flow 
cytometry analysis, we are not appreciating small differences in the changing DC population. 
Performing a more comprehensive flow cytometry DC panel may be helpful in parsing out the 
differences in cellular heterogeneity. 
As tissue-resident DCs mature, they acquire T-cell stimulatory capacity and are able to 
convert conventional naïve T cells to a Treg phenotype or promote Treg function(202). These 
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“repair” Tregs can be either CD4+ or CD8+, and have been suggested to promote wound healing 
and repair in multiple tissues(203). The increase in anti-inflammatory subtypes of innate immune 
cells made us interested in the trends in adaptive immunity by day 7 of treatment. SPADE 
analysis of CD4+ CD25+ Tregs did not show any trends in heterogeneity in response to 
treatment. Interestingly, however, SPADE revealed the surprising finding of CD8+ IL-10+ T-cell 
involvement. After developing a base CD3+ tree, we noticed a small subset of CD8+ cells that 
co-expressed IL-10. Tornado plot analysis indicated a trend towards treatment group in the dual 
hydrogel group. CD8+ Tregs have been shown to be a heterogeneous population, thus making 
them difficult to study using conventional methods, and as a result, are often poorly 
characterized(206). In fact, CD8+ Tregs have been reported in humans, and have strong 
immunosuppressive properties in vitro(207). CD8+ Tregs have also been shown to play a role in 
human autoimmune disease, including IBD(208). 
This data suggests a synergistic interplay between AT-RvD1 and IL-10 that allows for 
increased control of the recruitment of cells from the innate and adaptive immune system 
compared to either treatment on its own. Moreover, this data implicates an interesting role for 
CD8+ Tregs in the process of wound healing. This dual-delivery system has the potential to 
improve therapeutic wound healing outcomes following trauma or tissue transplantation via 
synergy of cellular recruitment and polarization processes to promote anti-inflammatory cell 








3.4 Materials and Methods 
3.4.1 Thiolation of IL-10 
Carrier-free recombinant human IL-10 was purchased from BioLegend. IL-10 was thiolated using 
30 molar excess of Traut’s reagent (Sigma) for one hour in PBS containing 0.1uL EDTA per uL 
buffer to chelate free metals. The thiolation reaction was shaken at RT for one hour. Thiolated IL-
10 was separated from unreacted Traut’s reagent using a Zeba desalting column according to 
manufacturer’s instructions. Thiolation was detected using a Measure-IT™ Thiol Assay Kit 
(Invitrogen) according to kit instructions. Number of thiol groups per IL-10 was calculated using 
the concentration of detected thiols and the known concentration of IL-10 in each measured 
sample. 
3.4.2 Hydrogel Fabrication 
Four-arm poly(ethylene glycol) (PEG, 10 kDA molecular weight) end-functionalized with 
maleimide (>95% purity, Laysan Bio) at 4.5% weight/volume was used for all hydrogel 
formulations. PEG macromers were functionalized with RGD peptide (GRGDSPC), crosslinked 
with the cysteine-flanked peptide VPM (GCRDVPMSMRGGDRCG) (AAPPTec) in 0.5M MES 
buffer, pH 5.5. The final concentration of RGD was 1.0mM. Gels were also loaded with 50ug/mL 
IL-10, and 4ug/mL AT-RvD1 (Cayman Chemical). The crosslinker concentration was based on 
the concentration of non-reacted maleimide groups remaining on PEG macromers. For hydrogels 
used in animal studies, all components were filtered through a spin column after pH 
measurements and kept under sterile conditions until injection into the animals. To generate pre-
formed hydrogels for release studies, the hydrogel was formed on a sterilized petri dish. After 
crossslinking, hydrogels were incubated at 37˚C for 15 minutes and then swelled in PBS for at 
least 30 minutes. Release of thiolated and unthiolated IL-10 was measured over time in 1% BSA 
solution using IL-10 tagged Alexa Fluor 405 NHS Ester (Life Technologies) according to the 
 49 
manufacturer’s recommendation and quantified using a standard curve of known fluorescent IL-
10 concentrations. Release of AT-RvD1 was measured with a Shimadzu UFLC High 
Performance Liquid Chromatograph (Columbia, MD, USA) equipped with a Shimadzu Premier 
C18, 5µm (250x4.6mm) column. AT-RvD1 elution was measured at 8.6 minutes using a 
wavelength of 301nm. Known quantities of AT-RvD1 were used to generate a standard curve 
relating AT-RvD1 mass to total peak area. Using serial dilutions, we determined that the limit of 
detection was below 0.5pg/µL. The total amount of AT-RvD1 in each release sample was 
calculated using the standard curve.  
3.4.3 Tissue Harvest and Flow Cytometry 
To collect samples for flow cytometry analysis, mice were euthanized via CO2 asphyxiation. The 
dorsal tissue was excised and digested with collagenase type 1-A (1mg/ml, Sigma) at 37°C for 30 
minutes and further separated with a cell strainer to create a single cell suspension. Single cell 
suspensions of dorsal tissue were stained for flow cytometry analysis using standard methods and 
analyzed on a FACS-AriaIIIu flow cytometer (BD Biosciences). Dead cells were excluded 
through staining using Zombie Red fixable viability stain (BioLegend). The antibodies used for 
identifying cell populations of interest were: PE conjugated MerTK (Biolegend), PE-Cy7 
conjugated MHC-II (BioLegend), BV605 conjugated CD206 (BioLegend), BV510 conjugated 
Ly6C (BioLegend), APC-Cy7 conjugated Ly6G (BioLegend), BV711 conjugated CD64 
(BioLegend), BV785 conjugated CD19 (BioLegend), APC conjugated Cd11b (BioLegend), 
BV421 conjugated CD11c (Biolegend, FITC conjugated CD86 (BioLegend), PerCP-Cy5.5 
conjugated CD3 (Biolegend), BV785 conjugated CD8 (BioLegend), BV605 conjugated CD4 
(BioLegend), and BV711 conjugated CD25 (BioLegend). Staining using BV dyes was performed 
in the presence of Brilliant Stain Buffer (BD Biosciences). Cells were stained for intracellular 
cytokines using PE conjugated IL-10 (BioLegend) and PE-Cy7 conjugated TNF- α 
(eBiosciences). Positivity was determined by gating on fluorescence minus one controls. 
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Absolute quantification of cell numbers was performed by adding 25μL of AccuCheck counting 
beads to flow cytometry samples (Thermo Fisher Scientific). 
3.4.4 SPADE analysis of flow cytometry data 
Dimensionality reduction analysis was performed using MATLAB-based Spanning-tree 
Progression Analysis of Density-normalized Events (SPADE). SPADE is a computational 
technique that performs density-dependent down-sampling, agglomerative clustering, linking 
clusters using minimum spanning-tree algorithm, and finally, up-samples based on user input. 
The SPADE trees generated here were generated by exporting compensated pre-gated single 
cells, CD11b+ myeloid cells, MerTK+ CD64+ cells; single cells, CD3-, CD11c+ cells; or pre-
gated single cells, CD3+ cells. The markers used to build the SPADE tree were SSC, FSC, 
CD11b, Ly6G, CD11c, CD64, CD86, CD206, CD8, CD4, CD25, Ly6C, IL-10, TNF-a. The 
following SPADE parameters were used: Apply compenstation matrix in FCS header, Arcsinh 
transformation with cofactor 150, neighborhood size 5, local density approximation factor 1.5, 
max allowable cells in pooled downsampled data 50000, target density 20000 cells remaining, 
and number of desired clusters 100. 
3.4.5 Statistical Analysis 
All statistical analyses were performed using Graphpad Prism version 6.0 (La Jolla, CA). Results 
are presented as mean ± standard error of the mean (SEM). For grouped analyses, one-way 
ANOVA with Tukey’s post-test was used for multiple comparisons. For internally controlled 
experiments, two-way ANOVA was used. Tukey’s post-hoc test was utilized when comparing 
paired samples, and Bonferroni’s post hoc test was used when comparing between treatment 





CHAPTER 4. INVESTIGATING THE LOCAL AND SYSTEMIC 
EFFECTS ON THE IMMUNE RESPONSE FOLLOWING ORAL 
GAVAGE OF IMMUNOMODULATORY MICROPARTICLE 
TREATMENT 
4.1 Introduction 
 Salmonella typhimurium is a Gram-negative pathogen that is acquired as a foodborne 
illness(209). Infection is limited to the intestinal mucosa, causing acute neutrophilic inflammation 
without epithelial destruction. After ingestion, Salmonella reaches the small intestine lumen, 
where it invades the epithelium of intestinal villi, or translocates across the epithelium to gain 
access to the Peyer’s patches or gastrointestinal lymphoid tissue (GALT), the overlaying mucosal 
lymphoid aggregates that are the immune sensors of the intestine(94). Another mechanism of 
pathogenesis may include infection of the dendritic cells (DCs) that extend processes across 
epithelial tight junctions to sample the contents of the lumen(210, 211). Thus, the pathogen 
affects innate immunity, infecting either DCs, neutrophils, or macrophages. Ultimately, the early 
immune response to Salmonella involves the accumulation of neutrophils and the development of 
a systemic inflammatory syndrome(212).  
Bacterial pathogens have been shown to prevent and reduce the immune response after 
initial infection and establishment within host cells(213). Some pathogens secrete proteins into 
the host via a “type III secretion apparatus” which allows for invasion and intracellular 
carriage(9). This may include mechanisms by which recruitment of phagocytic leukocytes is 
suppressed, and apoptosis of inflammatory cells is initiated to allow for bacterial proliferation and 
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dissemination. Notably, these proteins have been shown to exhibit these inhibitory actions against 
MAPK or NF- κB signaling pathways(214). Examples of these immunosuppressive factors are 
AvrA, from Salmonella, a member of the family of acetyltransferases that is expressed in several 
pathogens(215), YopJ/P from Yersinia pseudotuberculosis(216), and VopP from Vibrio 
parahemalyticus(217).  
 Salmonella AvrA has been shown to cause innate immune signaling blockade without 
causing cell death that is typically seen during host inflammatory inhibition. While cells infected 
with Salmonella can initiate apoptosis and activate pro-inflammatory processes, AvrA has been 
shown to dampen both host responses for the establishment of infection and avoidance of an 
adaptive immune response(218). Notably, loss of AvrA increased host cell apoptosis, and 
increased microbial burden beyond local inflammation to systemic lymphoid tissues, suggesting 
AvrA may play a role in limiting pathogenesis to a local infection(218). Previous reports show 
that AvrA exhibits these actions by acting as an acetyltransferase, blocking the actions of target 
MKK4/7(9). As a result, AvrA indirectly inhibits activation of downstream JNK signaling. In 
addition, although traditional bacterial pathogens, such as Shigella or enterohemorrhagic E. coli, 
initiate apoptosis of infected cells, AvrA inhibits apoptosis pathways, preventing the elimination 
of host cells(9).  
 The combined properties of AvrA to inhibit the inflammatory response while preventing 
cell death suggests that AvrA may be a potent and local therapeutic for the treatment of 
inflammatory disease. Inflammatory bowel disease (IBD) affects 3.1 million people in the United 
States, and its incidence appears to be on the rise(219, 220). Crohn’s disease (CD) and ulcerative 
colitis (UC), two major forms of IBD, and are chronic inflammatory disorders of the 
gastrointestinal tract. Current therapeutics include small molecules, systemic corticosteroids, 
monoclonal antibodies, and, in the case of UC, surgical removal of the entire colon(221). These 
therapeutics are typically effective for some time, but have extensive side effects and, ultimately, 
patients become unresponsive and must be switched to new medication. Recent literature has 
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suggested that AvrA, with its dual anti-inflammatory and anti-apoptotic functions, may be a 
potential agent to ameliorate inflammation in IBD(222). In order to utilize the unique aspects of 
AvrA, it was necessary to deliver it to the gastrointestinal tract for it to come into contact with the 
intestinal epithelium and local immune cells.  
 Efficient drug delivery system must meet several requirements to serve as an ideal 
delivery vehicle of an active therapeutic. Such requirements include improved stability, reduced 
dosage and frequency of administration, reduced side effects, minimum toxicity, and the ability to 
deliver the required amount to the target location for a long time(223). Techniques in 
nanotechnology have led to the development of different types of carriers for controlled release 
and targeted delivery. Previous IBD studies have attempted to deliver therapeutics in the form of 
biodegradable polymeric nano- and microparticles (144, 224). However, among nanoparticle 
technologies, the ability to be synthesized from naturally occurring or engineered proteins 
provide a promising method for drug delivery application. Protein-based carriers are nontoxic, 
biodegradable, and can be degraded by physiological changes or by enzymes present in the 
body(225). Protein NPs also increase cellular internalization and have high protein loading 
capacities. Further, protein NPs can passively target enflamed tissue(226). Thus, we previously 
developed AvrA nanoparticles for the therapeutic targeting of IBD(227). However, delivery to the 
gastrointestinal tract proves difficult due to the harsh environment in the stomach. The gastric 
system possesses low pH and a number of digestive enzymes whose goals are to break down and 
digest proteins. For effective and convenient administration of drugs, pH- and ion-responsive 
polymers have been employed for site-specific drug release(228). For example, anionic polymers 
have been used for delivery to the colon due to their responsiveness to high intestinal pH 
preventing gastric degradation of the drug(228).   
 In order to effectively deliver AvrA NPs to the small intestine, we developed an approach 
to deliver therapeutic proteins encapsulated within gastro-protecting alginate and chitosan 
microparticles (MPs). Alginate and chitosan are naturally derived biocompatible polymers that 
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have been extensively applied for controlled drug release(229, 230). Alginate is commonly used 
for the encapsulation of therapeutic agents(231), and is the most studied material for 
encapsulating live cells(232). Chitosan is a cationic polysaccharide, and has numerous favorable 
biological properties, such as non-toxicity and mucoadhesive properties(52, 233). Alginate can 
form hydrogels in the presence of divalent cations that interact with carboxylic groups in the 
alginate backbone(234). Chitosan was chosen to coat the alginate particles to prevent drug 
leakage. The complementary electrostatic properties of anionic alginate and cationic chitosan 
create interpolymeric associations that are strengthened by the protonation of chitosan at low 
pH(235). However, at intestinal pH, which is more basic, alginate gels swell, and the chitosan 
charge becomes negative. This allows for the release of AvrA specifically in the more basic 
environment of the intestine.   
 The absorptive environment of the GI tract suggests that the released AvrA nanoparticles 
may be taken up directly by either the absorptive epithelium/intraepithelial lymphocytes (IELs), 
or in the Peyer’s patches(236). It has been shown that early infection is established within 
macrophages, then rapidly spreads to phagocytic cells of the splenic reticuloendothelial system. 
Thus, we aimed to identify whether the regulation of inflammation by orally delivered AvrA 
would follow a similar mechanism of immune suppression. Moreover, we hypothesized that local 
delivery of AvrA microparticles would inhibit the immune response in the Peyer’s patches, but 






Figure 7. AvrA microparticle synthesis.  
 
Schematic representation of AvrA NP loading into alginate droplets via flow focusing 













4.2.1 AvrA MPs reduce local innate immunity in the gastrointestinal system 
AvrA protein NPs were manufactured by desolvation of eGFP and AvrA with ethanol 
under constant stirring, followed by crosslinking with 3,3’-dithiobis-(sulfoccinimidylpropionate) 
(DTSSP) for stabilization(237). AvrA NPs were then mixed with alginate and droplets were 
formed using a flow focused microfluidic device. The droplets were directed into a bath 
containing chitosan and CaCl2 ( 
 
 
Figure 7). To study the role of AvrA on intestinal infection in vivo, we treated mice with 
either AvrA MPS or control by oral gavage for 5 days. Three groups of female mice were then 
administered either E. coli lipopolysaccharide (LPS) or PBS for 24 hours. After sacrifice, we 
digested Peyer’s patches from the small intestine, following which we isolated epithelial cells and 
intraepithelial lymphocytes from the small intestine lamina propria for flow cytometry (Figure 
8A). In typical Salmonella infection, neutrophils migrate across the epithelial barrier to the apical 
membrane(238). This suggests that in response to infection, neutrophils are the first responders 
and may influence intestinal epithelial functions and the subsequent immune response(239). 
Thus, we hypothesized that treatment with AvrA would reduce neutrophil infiltration into the 
epithelium, and particularly into the Peyer’s patches.  
In order to test this, after treatment with AvrA and LPS, we sacrificed the animals and 
quantified neutrophils by identifying CD11b+ Ly6G+ and activation levels of intracellular 
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epithelial (E-cadherin+) TNF. We also quantified macrophages using CD11b+ F4/80+ cells, as 
previous research has shown that macrophages transduced with AvrA expressing adenovirus were 
protected from apoptosis induced by exogenous stimuli, indicating that macrophages are a 
potential target for the immune suppression caused by AvrA(240). We particularly focused on 
cell populations  from the intraepithelial/intraepithelial lymphocytes (EC), small intestine lamina 
propria (SI), and Peyer’s patches (PP). 
Interestingly, we observed a reduction of intracellular TNF in the EC (Figure 8B). 
Moreover, we observed a local reduction of neutrophils in the PP, but not in the intraepithelial 
lymphocytes or SI (Figure 8D).This early response at 24 hours following infection suggests an 
immediate inhibition of neutrophil transmigration across the intestinal epithelium in the PP(240). 
The inhibition of neutrophil migration and the additional reduction of TNF in epithelial cells 
potentially suggests that migrating neutrophils may signal to the epithelium. However, we did not 
notice changes in macrophage numbers following stimulation with LPS or following treatment 







Figure 8 Treatment with AvrA influences the innate immune system following E. coli LPS 
stimulation.  
(A) C57bl/6 mice were treated with either AvrA or control (PBS) for 5 days. LPS or vehicle was 
administered, and mice were sacrificed after 24 hours. Mouse small intestine was isolated and 
processed to separate intraepithelial lymphocytes (EC) from small intestine lamina propria (SI). 
(B) Intracellular expression of TNF in epithelial cells was determined by flow cytometry. (C) 
F4/80+ CD11b+ macrophages were quantified for each treatment group: PBS+intraperitoneal PBS, 
control PBS+LPS, or AvrA microparticles+LPS. (D) No significant changes in neutrophils in EC 
or SI were observed; however, a significant reduction of neutrophil infiltration in the Peyer’s 
patches was observed between control PBS+LPS versus AvrA microparticle+LPS groups. Data 
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presented as mean ± SEM. Statistical analysis was performed using two-way repeated measures 
ANOVA with Tukey’s post-hoc test. *p<0.05, **p<0.01, n=3.  
4.2.2 AvrA reduces local adaptive immunity in the gastrointestinal system 
We then wanted to investigate whether the modulation of innate immunity had effects on 
the adaptive immune system. In the same animals that were treated with AvrA or control, we 
identified CD3+ T-cells to further elucidate the roles of individual subpopulations (Figure 9A). 
Out of CD3+ T-cells we identified T-helper cells, also known as CD4+ T-cells, and cytotoxic T-
cells, or CD8+ T-cells, in samples isolated from the IELs, small intestine lamina propria, and 
Peyer’s patches.  
Interestingly, we found a reduction in CD4+ T-cells in the Peyer’s patches and no 
changes in the IELs or small intestine (Figure 9B). In contrast, we noticed a reduced CD8+ 
population in the IELs, but no significant changes in either small intestine or Peyer’s patches 
(Figure 9C). This suggests potential interesting role for CD4+ and CD8+ T-cells in the 






Figure 9 Treatment with AvrA influences adaptive immunity.  
(A) C57bl/6 mice were treated with either AvrA or control (PBS) for 5 days. LPS or vehicle was 
administered, and mice were sacrificed after 24 hours. Mouse small intestine was isolated and 
processed to separate intraepithelial lymphocytes (EC) from small intestine lamina propria (SI). 
(B) Flow cytometric analysis reveals a reduction in CD4+ T-cells in Peyer’s patches, but no 
differences in EC or SI. (C) CD8+ T-cells were reduced in EC cells that were treated with AvrA 
microparticles when compared to control PBS+LPS, but no changes were observed in SI or Peyer’s 
patches. Data presented as mean ± SEM. Statistical analysis was performed using two-way repeated 
measures ANOVA with Tukey’s post-hoc test. *p<0.05, **p<0.01, n=3.  
 
4.2.3 Local delivery of oral AvrA microparticles likely do not acutely affect systemic immunity  
In typical Salmonella infection, the infection rapidly disseminates to cells within the 
splenic reticuloendothelial system(212). Thus, we were interested to investigate whether local 
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delivery of AvrA microparticles would result in only a local immune modulation or whether its 
signalling effects would influence systemic immunity as well. Thus, we isolated and prepared 
spleens for flow cytometry from wild-type mice that had been pre-gavaged with AvrA 
microparticles or controls for 5 days, and then administered intraperitoneal LPS or intraperitoneal 
PBS (Error! Reference source not found.A).  
We stained for innate immune cells, including neutrophils (CD11b+ Ly6G+), 
macrophages (CD11b+, F4/80+), and T-cells, including CD3+ CD4+ and CD3+ CD8+ T-cells. 
Although neutrophil and T-cell infiltration was reduced in the local GI tract, there were no 
changes observed in either innate (Error! Reference source not found.B) or adaptive immune 
















Figure 10. Effects of orally administered AvrA likely do not result in systemic 
immunosuppression. 
C57bl/6 mice were treated with either AvrA or control (PBS) for 5 days. LPS or vehicle 
was administered, and mice were sacrificed after 24 hours. Mouse spleens were isolated 
for staining. Flow cytometric analysis shows no changes in neutrophils (A) or 
macrophages (B) in mice treated with PBS control + PBS vehicle (black), PBS 
control+LPS (light gray), or AvrA microparticles+LPS (dark gray). This analysis did not 
show any changes in CD4+ (C) or CD8+ (D) cell populations in either PBS or AvrA 
microparticle treatment. Statistical analysis was performed using two-way repeated 
measures ANOVA with Tukey’s post-hoc test. *p<0.05, **p<0.01, ***p<0.001, n=3. 
4.2.4 Marker expression heatmaps allow for phenotype interpretation 
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Observing the amelioration of innate immune cell recruitment from both GALT and IELs 
suggested a more extensive picture of the spatial dynamics of the innate and adaptive immune 
systems. Thus, we sought to organize the multidimensional dataset observed in response to LPS 
and AvrA microparticle treatment. In order to conduct a non-biased, unsupervised analysis of 
phenotypic differences between treatment groups, we used Spanning-tree Progression Analysis of 
Density-normalized Events (SPADE) to identify populations of cells. SPADE is an invaluable 
tool to analyze multidimensional flow cytometry data. The SPADE algorithm clusters similar 
populations into nodes and projects them into a tree. Each node contains cells with similar marker 
expression across all parameters, and the size indicates the number of cells within a population. 
To more clearly visualize our dataset, the marker expression per node was then hierarchically 
clustered using R Studio to make conclusions about cell phenotypes at each time point  The 
identified cell populations included CD11b+ Ly6G+ (neutrophils), dendritic cells (CD11b-
CD11c+), T-cells (CD11b-, CD3+), and CD4+ T-Cells (CD11b-, CD3+, CD4+). Interestingly, we 
observed a third population of T-cells that stained for Ly6C+, CD3+, AND CD8+ in 5 nodes 























Figure 11. Expression of phenotypic markers used for node characterization.  
Median expression for each marker was averaged for all 100 nodes. Results are shown on heatmap following 
unsupervised hierarchical clustering. Color intensity indicates expression level. Combined expression of 
different markers was used to identify traditional immune populations, as well as rare cell subsets. 
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4.2.5 Node distribution shows different proportions in AvrA Peyer’s patches compared to 
controls 
Identification of the unique population of CD8+ T-cells led us to compare proportions of 
adaptive immune cells between control and AvrA treated mice. We developed a base SPADE tree 
for CD3+ T-cells (Figure 12A) and identified CD4+ cells (Figure 12B) in 
epithelial/intraepithelial lymphocytes (EC), small intestine lamina propria (SI), and Peyer’s 
patches (PP) populations. We identified six nodes that were CD3+ CD4+. In those nodes, we 
exported the cell frequencies in the control+LPS group and the AvrA+LPS group. To determine 
the difference in cell frequencies in the six nodes, we subtracted control from treatment and 
created tornado plots in order to highlight SPADE nodes with important variations in cell 
proportions. Nodes were ranked in descending order according to their subtracted proportions 
between control (n=3) and treatment (n=3). A difference under 0 reflected an abundance of CD4+ 
cells in treatment groups, whereas a positive difference suggested an increased node proportion in 
the control+LPS group. The differences in cell frequencies were then plotted (Figure 12C) and 
compared to the results obtained from flow cytometry (Figure 12D). The trends in cellular 
heterogeneity reflect the abundance of CD4+ T-cells in control samples with no nodes occupied 
by CD4+ T-cells in the AvrA treatment group.  
Since the SPADE trends validated the shift of cells towards LPS-treated controls in 
accordance with the raw flow cytometry data, we aimed to elucidate the role of the novel CD8+ 
Ly6C+ cells in control versus treatment groups. Thus, we created SPADE trees for CD3+ CD8+ 
T-cells (Figure 13A). Interestingly, from the heatmap, we noticed some nodes had overlapping 
expression of CD8+ and Ly6C+ cells. Thus, we then created a SPADE tree for CD3+ CD8+ 
Ly6C+ nodes to elucidate this unexpected cell population (Figure 13B). Potentially increased or 
decreased nodes’ frequencies were plotted for control, control+LPS, and treatment+LPS groups 
with individual values based on the four nodes that were identified from the CD3+ base tree. We 
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analyzed node frequencies across these four nodes and found reduced CD8+ Ly6C+ cells in three 
of the four nodes, #45, #64, and #89, with a statistically significant reduction in cell proportion in 
AvrA treated groups in node #89 (Figure 13C). However, when analyzing the raw flow 
cytometry data, though the AvrA group trended towards reduced CD8+ Ly6C+ cell populations, 
we did not observe the shift in cellular heterogeneity from the raw flow data (Figure 13D). CD8+ 
T-cells were originally added to the panel for completion, and we did not initially expect to see 
any changes in this subpopulation of cells. These data suggest a shift in pseudotime, indicating 
that LPS stimulation increases CD8+ Ly6C+ cells, which are reduced in treated groups.  
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Figure 12 SPADE allows for the identification of characteristic immune populations. 
A) A CD3+ base tree was developed after gating for CD3+ T-cells. (B) SPADE analysis indicates nodes 
positive for CD4+ cells. (C) Cell frequency within each identified node was exported and the difference 
in cell frequency was plotted on a tornado plot by subtracting control+LPS from the AvrA treatment 
group. (D) Flow cytometric analysis of CD4+ cells were plotted for comparison. Data presented as mean 
± SEM. Statistical analysis was performed using two-way repeated measures ANOVA with Tukey’s 





Figure 13  SPADE allows for the quantification of known and rare immune cell subsets.  
(A) A CD3+ base tree was developed after gating for CD3+ T-cells. (B) CD8+ Ly6C+ nodes were also 
identified from the CD3+ base tree. (C) Cell frequencies within each of the four nodes was exported and 
plotted on a graph to compare control, control+LPS, and AvrA+LPS. (D) CD8+ Ly6C+ cell populations 
were analyzed from raw flow cytometry data. Data presented as mean ± SEM. Statistical analysis was 




4.2.6 Salmonella LPS induces both systemic and gastrointestinal inflammation 
Unfortunately, E. coli LPS stimulation did not produce as robust of an immune 
response as was expected, particularly in the gastrointestinal tract. In order to validate our 
findings of the CD8+ Ly6C+ subpopulation of T-cells, we needed to establish a more 
robust model of acute inflammation. Because immune stimulation is necessary to identify 
the local and systemic effects of AvrA, we aimed to identify a strain of LPS that would 
induce inflammation both locally and systemically. LPS are complex amphiphilic 
molecules that are released from the bacterial cell wall by shedding or through lysis, and 
are found in the outer membrane of Gram-negative bacteria (241, 242). Thus, we decided 
to compare LPS isolated from Salmonella Typhimurium to that from E. coli. S. 
Typhimurium causes self-limiting gastroenteritis in humans and severe inflammation of 
the intestinal mucosal epithelial, and can also cause systemic infection(243). Thus, LPS 
from S. Typhimurium would likely allow us to investigate the influence of LPS locally 
versus systemically. 
 To test this, we treated wild-type mice with both strains of LPS for 24 hours, 
following which we isolated terminal ileum and spleen for RT-PCR analysis. In the 
terminal ileum, E. coli LPS did not show a change IL-1β or TNF, two inflammatory 
cytokines (Figure 14A), whereas LPS from S. Typhimurium showed a significant increase 
in both cytokines (Figure 14C). In the spleen, both strains showed a robust increase in 











Figure 14. In vivo inflammatory response to E. coli and S. typhimurium. 
C57bl/6 mice were given LPS intraperitoneally isolated from E. coli or S. typhimurium. 
Inflammatory cytokines were measured 24 hours after infection using RT-PCR. TNF and IL-1β 
were measured in E. coli infected terminal ileum (A) and spleen (B), as well as in S. typhimurium 
infected terminal ileum (C) and spleen (D). Statistical analyses were conducted using a one-tailed t-
test. *p<0.05, **p<0.01, ***p<0.001, across 2-3 animals per group. 
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 C57bl/6 mice were treated with either PBS alone, PBS+LPS, empty microparticle (CTL 
MP) alone, CTL MP+LPS, AvrA MP alone (AvrA), or AvrA+LPS, and were sacrificed 
after 24 hours. Flow cytometric analysis was performed for neutrophils (Ly6G+) (A), 
CD4+ T-cells (B), CD8+ T-cells (C), and CD8+ Ly6C+ CD44+ T-cells (D). Statistical 
analysis was performed using two-way repeated measures ANOVA with Tukey’s post-
hoc test. *p<0.05, **p<0.01, ***p<0.001, n=4. 
 
 





4.2.7 LPS derived from S. Typhimurium induces gastrointestinal and systemic 
inflammation  
To study the role of AvrA in a robust model of acute inflammation, we organized 
treatment groups into PBS alone, PBS+LPS, empty microparticles (CTL MP), CTL MP+LPS, 
AvrA alone, and AvrA+LPS. Empty microparticles were manufactured by mixing alginate with 
PBS before loading into the microfluidic device. We pre-treated mice with each treatment group 
for 5 days, after which we administered intraperitoneal LPS for 1 day. After sacrifice, we isolated 
epithelial cells and intraepithelial lymphocytes from the small intestine lamina propria for flow 
cytometry, and identified CD11b+ Ly6G+ (Figure 15A), CD4+ T-cells (Figure 15B), CD8+ T-
cells (Figure 15C), as well as the CD8+ Ly6C+ population of cells that was identified by 
SPADE. We also included CD44+, which is a marker of T-cell activation. We noticed a more 
robust inflammatory response following intraperitoneal injection of this strain of LPS. Moreover, 
we observed a reduction of Ly6G+ neutrophils in AvrA treated groups when compared to 
treatment groups. We also observed a significant reduction in CD8+ T-cells in AvrA compared to 
both PBS and CTL MPs. Lastly, we also noticed a reduction in CD8+ Ly6C+ CD44+ cells after 
AvrA treatment compared to both controls. We did not observe significant changes in the CD4+ 
T-cell population. Lastly, we also did not notice changes in macrophage numbers following 
stimulation with LPS or following treatment with AvrA (not shown). 
Importantly, we did observe a robust increase in splenic immune cell populations, 
including neutrophils (Figure 16A), macrophages (Figure 16B), and CD8+ T-cells (Figure 
16D). There were no differences observed between any of the treatment groups in any of the 
immune cell subsets. Additionally, CD4+ T-cells (Figure 16C) and CD8+ Ly6C+ CD44+ 






C57bl/6 mice were treated with either PBS alone, PBS+LPS, empty microparticle (CTL) 
alone, CTL MP+LPS, AvrA MP alone (AvrA), or AvrA+LPS, and were sacrificed after 
24 hours. Each spleen was homogenized and processed for flow cytometry. Cell subsets 
analyzed included neutrophils (CD11b+ Ly6G+) (A), macrophages (CD11b+ F4/80+), 
CD4+ T-cells (C), CD8+ T-cells (D), and CD8+ Ly6C+ CD44+ T-cells (E). Statistical 
analysis was performed using two-way repeated measures ANOVA with Tukey’s post-





Figure 16. LPS from S. Typhimurium induces a robust systemic immune response 
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4.3 Discussion 
AvrA is an enzyme derived from Salmonella that is able to modulate the immune system 
and influence apoptotic cellular pathways. We have previously shown that AvrA nanoparticles 
are a clinically viable method of reducing inflammation in the gastrointestinal tract(227). In order 
to deliver AvrA orally, we previously developed gastro-protective alginate/chitosan MPs that 
have site-specific effects in the small intestine and colon(8). Here, we wanted to elucidate the 
spatial distribution of the immune response to AvrA microparticles. The intestinal mucosal 
immune system is made up of three major areas: the small intestine lamina propria (LP), the 
intraepithelial lymphocytes (IEL), and Peyer’s patches (PP). These different immune centers 
create a complex network to adequately mount an immune response in the intestine. IELs contain 
large numbers of T-cells with CD8+ T-cells predominating, whereas the LP is made up of 60% T-
cells and 40% B-cells(244, 245). The LP and IELs contain diffusely distributed lymphocytes and 
contain mostly effector populations. Notably, the IEL populations exhibit minimal recirculation, 
indicating their functions are limited particularly to the GI tissue(246).  
PPs are aggregated lymphoid follicles that collectively make up the GALT(247). This 
lymphoid tissue is separated into three main areas: the follicular area, interfollicular area, and 
follicle-associated epithelium (FAE). The follicular and interfollicular areas contain a germinal 
center (GC), which is made up of proliferative B-lymphocytes, follicular dendritic cells (FDCs), 
and macrophages. Outside of this area is the corona, made up of B-cells, T-cells, macrophages, 
and DCs(94). The FAE contains both epithelial cells and M-cells, specialized cells involved in the 
transcytosis of luminal material. In the mouse, PPs contain 60% B-cells (B220+); 25% T-cells 
(CD3+), with 45% CD4+ cells, 35% CD8+, and 20% CD4-/CD8- cells; 10% DCs (CD11c+); and 
around 5% macrophages (F4/80+) or neutrophils (Ly6G+)(248). There also exists a CD11c+ 
CD8a+ CD11b- DC population within the interfollicular region(249, 250). Targeting cells in the 
PP has become a strategy for oral therapeutics because of its important role in the mucosal 
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immune system and due to its constant sampling of the intestinal lumen(251, 252). The PP also 
have been shown to uptake of nanoparticles through the lymphatic system(253). 
Here, we show that AvrA MPs influence local innate and adaptive immunity at several 
layers of GI immunity. First, we demonstrate that AvrA MPs influenced innate immunity in the 
PPs and epithelium. Notably, we observed a reduction in intracellular TNF in the intestinal 
epithelium. Epithelial cells (ECs) play an important role in maintaining integrity of the mucosal 
barrier, and is an important mediator in signaling to the surrounding immune 
microenvironment(254). In addition, we observed a reduction in neutrophil populations in mice 
treated with AvrA microparticles in the local PPs when compared to controls as well as a 
reduction in CD4+ T-cells. Lastly, we found a significant decrease of CD8+ T-cells in the IELs 
after AvrA microparticle treatment.  
In order to confirm reliability of our data, we validated our work using non-supervised 
dimensionality reduction approach. Thus, we used SPADE to highlight novel aspects of immune 
alterations developed after immunomodulatory hydrogel treatment. SPADE is a dimensionality 
reduction technique that hierarchically clusters phenotypically similar cells into “nodes”. These 
nodes and their relationships are organized into a minimum spanning tree, or “SPADE tree”. We 
then created a heatmap to create a 2D visualization representing marker expression of each node 
for all the markers used. Using SPADE analysis, we were able to confirm that AvrA treatment 
results reduced CD4+ T-cells in the PPs. However, on our heatmap, we also noticed 4-5 nodes 
that were positive for Ly6C+ and CD8+ T-cells. When we explored this on our SPADE tree, we 
confirmed a population of CD8+ T-cells that co-expressed Ly6C+. Ly6C is an activation marker 
of CD8+ T-cells, potentially indicating that, in a more robust model of inflammation, AvrA is 
inhibiting the activation status of this subset of T-cells(255). Previous studies also suggest that 
Ly6C+ expression on naïve CD8+ T-cells may be involved in the effector fate of this subset of T-
cells(256).  
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In order to elucidate the effects of CD8+ Ly6C+ T-cells, we aimed to identify a more 
robust method to induce acute inflammation. After testing strains of LPS isolated from 
Salmonella typhimurium and E. coli, we established that S. tymphimurium infection causes both 
systemic and GI inflammation. We then separated mice into a control PBS group, a control empty 
alginate/chitosan microparticle group (CTL MPs), and an AvrA treatment group, and mice were 
treated for 5 days prior to LPS stimulation. Half of each group (n=4) received S. typhimurium 
LPS administration intraperitoneally, while the other half (n=4) received intraperitoneal 
administration of vehicle(257). Interestingly, when we attempted to isolate PPs for flow 
cytometry, we were unable to find any in the AvrA+LPS treated groups, and thus decided to 
focus on IELs and spleen. Within the IEL immune population, we found that AvrA MP treatment 
caused a reduction in Ly6G+ neutrophils, and a significant reduction in CD8+ T-cells. CD4+ T-
cells were not affected by either LPS or AvrA treatment. Within our adaptive immune cell panel, 
we included CD44+ as a marker for T-cells, as CD44 is an activation-associated surface marker 
on T-cells in order to confirm the presence of CD8+ Ly6C+ effector T-cells. As a result, we 
noticed a reduction in CD8+ Ly6C+ CD44+ cells. However, 24 hours is too short of a time frame 
to truly visualize the effects on T-lymphocytes. In order to get a full appreciation of the effects on 
this adaptive immune cell population, it would be necessary to sacrifice animals around 72 hours 
following LPS stimulation. These data suggest that AvrA results in an amelioration of the innate 
immune response at several levels of the GI immune system. More interestingly, however, AvrA 
seems to modulate the activation of CD8+ T-cells, potentially playing an immunosuppressive role 
on the adaptive immune system. Lastly, the usage of SPADE analysis allowed discrimination of 
rare cell subsets, highlighting new features of the immune response to explore while developing 





4.4.1 Synthesis of AvrA nanoparticles 
eGFP and AvrA nanoparticles were prepared as previously described(8). In brief, eGFP 
was expressed in BL21 Escherichia coli with chloramphenicol (VWR) in 2XYT media. eGFP 
was purified on Ni-NTA agarose (Qiagen) following imidazole purification. AvrA was contained 
in a plasmid (GE Lifesciences) and expressed in AFIQ Escherichia coli with chloramphenicol and 
ampicillin in 2XYT media. AvrA bacterial cultures were grown to o.d. 0.7 at 37ºC and induced 
with 0.4 mM isopropyl B-D-thiogalactoside (IPTG) at 25ºC for 4 hours. AvrA was purified with 
glutathione sepharose 4B (GE Healthcare), then repurified on Ni-NTA agarose following 
manufacturer’s native imidazole purification. Purified proteins were concentrated using 10k 
MWCO centrifugal ultrafiltration devices (Milipore) using eGFP concenrations of ~12mg/ml and 
1mg/ml AvrA in elution buffer.  
4.4.2 AvrA and eGFP Nanoparticle Synthesis 
Protein nanoparticles were prepared by desolvation as previously described(258). 50 µl 
of eGFP and 50 µl of AvrA were combined in a glass vial. The combined solution was desolvated 
via continuous, drop-by-drop addition of 400 µl ethanol at an addition rate of 1 ml/min. After 
desolvation, particles were crosslinked with 5 mg/ml Dithiobis(sulfosuccinimidyl-propionate) 
(DTSSP; Pierce) at a 1:2.2 ratio. After stirring for 90 minutes, cross-linking was stopped by 
centrifugation at 500 g for 5 min. Particles were re-suspended in PBS and sonicated on ice (1s on, 
3s off, 50% amplitude, 1 minute). 
4.4.3 Nanoparticle characterization 
Average particle size was calculated as the mean of 2 batches of particles. NP concentration was 
determined using a BCA assay (Pierce) following manufacturer’s protocol. Gel electrophoresis 
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was used to determine NP composition. Briefly, 50 µg of NP were heated in sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (50 mM Tris-Cl, pH 6.8, 
2% SDS, 100 mM DTT, 0.1% bromophenol blue, 10% glycerol), for 5 minutes. Proteins were 
transferred to nitrocellulose membrane and labelled with an Alexa-Fluor 488 conjugated penta-
his antibody (Qiagen) for imaging.  
4.4.4 Microfluidic device preparation 
A silicon master wafer was fabricated using multi-layer soft lithography and was 
generously gifted from Emily Jackson-Holmes and Professor Hang Lu. Polydimethylsiloxane 
(PDMS) devices (Sylgard 184, Dow Corning) were prepared at a 10:1 base to crosslinker ratio. 
The mixture was degassed for 1 hour at 70ºC. PDMS was poured onto the master wafer and cured 
overnight. PDMS was then cut from the master wafer molds, and inlet and outlet channels were 
created using 18-gauge needles. Each device was plasma treated (PDC-32G plasma cleaner) and 
bonded onto glass slides. PDMS devices were stored at room temperature until needed. 
4.4.5 Microparticle fabrication 
Low viscosity alginate (4% w/v) Protanal LF 200FTS, FMC Biopolymers) was dissolved 
in deionized water (DI) overnight. Protein NPs or PBS (empty microparticles, Sigma) were 
comined with alginate solution to a final alginate concentration of 2% w/v. The alginate/NP/PBS 
mixture was loaded into a 10 ml syringe with a 20-gauge needle (dispersed phase). 1% Span 80 
(TCI America) in mineral oil (VWR) was loaded into a 60-ml syringe with a 20-gauge needle 
(continuous phase). The syringes were loaded on two syringe pumps and the needles were 
connected to the microfluidic device. The flow rate of the dispersed phase was loaded as 10 
µl/min, and the flow rate of the oil phase was 50 µl/min.  
The outflow of the microfluidic device was dropped into a solution of 0.5% chitosan 
(85% deacetylated, Alfa Aesar) and 0.1% CaCl2 (VWR) at a final pH of 5.5. The device was 
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allowed to run overnight at constant stirring. Alginate/chitosan MPs were collected the following 
morning and washed at 500g, and resuspended in DI water until no more oil was observed. 200 
µL of chitosan-coated alginate MPs were imaged on bright-field microscopy to measure MP 
diameter. 
4.4.6 LPS stimulation of C57bl/6 mice 
Care of experimental animals was performed in accordance with Emory University 
IACUC guidelines. C57BL/6 mice were fasted overnight and treatment groups (n=4) were 
administered with 4 mg empty MPs, 4 mg AvrA NPs in MPs, or PBS via oral gavage. Total 
volume of gavage was 200 µl. Mice were gavaged once a day at the same time for 5 days prior to 
LPS stimulation. LPS was prepared using a stock from either Escherichia coli 0111:B4 under 
sterile conditions to a working concentration of 0.2 µg/µl. Female mice were weighed and 10 µl/g 
body weight of LPS was administered intraperitoneally. Mice were monitored for 24 hours, 
including observing fur appearance, activity, level of consciousness, and respiration rate. After 24 
hours, spleen, Peyer’s patches, and small intestine were isolated and processed for RT-PCR or 
flow cytometry.  
4.4.7 RT-PCR  
For transcriptional analysis, spleen and small intestine (terminal ileum) were dissected 
and processed. Terminal ileum was identified as the tissue about 1.5 cm proximal to the cecum. 
Tissue was mechanically disrupted in Trizol using a MagnaLyser with MagnaLyser beads. RNA 
was prepared according to manufacturer’s instructions. RT-PCR was performed using SybrGreen 






Table 1 RT-PCR Primers for Inflammatory Cytokines 









TNF TCTTCTCGAACCCCGAGTGA CCTCTGATGGCACCACCAG 
 
Data was normalized to Actin. In addition, data was analysed using 2ddCt method. 
4.4.8 Tissue Harvest and Flow Cytometry 
To collect samples for flow cytometry analysis, mice were euthanized via CO2 
asphyxiation and digested according to previously described protocol(259). Briefly, Peyer’s 
patches and spleen were identified and isolated using scissors. Tissue from both PPs and spleen 
was separated with a 100 µm cell strainer to create a single cell suspension. Small intestine was 
isolated and flushed with cold PBS. Tissue segments were placed in extraction media (Hank’s 
Buffered Salt Solution, Millipore Sigma, 5 mM EDTA, 10 mM HEPES) and incubated for 15 
minutes while shaking at 37ºC. 
After incubation, the supernatant containing epithelial cell and intraepithelial 
lymphocytes was isolated using a 100 µm cell strainer. The remaining small intestinal tissue was 
placed into 6 ml of digestion media (RPMI, Millipore Sigma, 1 mg/ml collagenase V) and 
vigorously shaken at 37ºC. The digested tissue was filtered through a 100 µm strainer and rinsed 
with RPMI containing 10% FBS. The four solutions, containing epithelial cells, small intestine, 
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spleen, and Peyer’s patches, were centrifuged at 800 x g for 5 minutes at 4ºC. The cell pellet was 
resuspended in 1 ml RPMI containing 2% FBS. Single cell suspensions were stained for flow 
cytometry analysis using standard methods and analysed on a BD LSRFortessa (BD Biosciences).  
Dead cells were excluded through staining using Zombie UV fixable viability stain 
(BioLegend). The antibodies used for identifying cell populations were: PerCP conjugated CD3 
(BioLegend), BV605 conjugated CD4 (BioLegend), BV785 conjugated CD8, APC-Cy7-
conjugated Ly6G (BioLegend), BV510-conjugated CD11b (BioLegend), BV711-conjugated 
Ly6C (BioLegend), BV421 conjugated CD11c (BioLegend), PE-Cy7 conjugated E-Cadherin 
(BioLegend), APC conjugated F4/80 (BioLegend), PE conjugated TNF (BioLegend), and Alexa 
Fluor 488 conjugated CD44 (BioLegend). Staining using BV dyes was performed using Brilliant 
Stain Buffer (BD Biosciences). Cells were stained for intracellular cytokines using a 
Fixation/Permeabilization Solution Kit (BD Biosciences). Absolute quantification of cell numbers 
was performed by adding 30 µl of CountBright Absolute Counting Beads (Thermo Fisher 
Scientific) to flow cytometry samples. 
4.4.9 SPADE analysis 
Dimensionality reduction analysis was performed using MATLAB-based Spanning-tree 
Progression Analysis of Density-normalized Events (SPADE). SPADE is a computational 
technique that performs density-dependent down-sampling, agglomerative clustering, linking 
clusters using minimum spanning-tree algorithm, and finally, up-samples based on user input. 
The SPADE trees generated here were generated by exporting compensated pre-gated single 
cells. The markers used to build the SPADE tree were SSC, FSC, CD11b, Ly6G, CD11c, CD8, 
CD4, E-Cadherin, Ly6C, CD44, and TNF-a. The following SPADE parameters were used: Apply 
compensation matrix in FCS header, Arcsinh transformation with cofactor 150, neighborhood 
size 5, local density approximation factor 1.5, max allowable cells in pooled downsampled data 
50000, target density 20000 cells remaining, and number of desired clusters 100. 
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4.4.10 Statistical analysis  
All statistical analyses were performed using Graphpad Prism version 7.0d (La Jolla, 
CA). Results are reported as mean ± standard error of the mean (SEM). For grouped analyses, 
one-way ANOVA with Tukey’s post-test was used for multiple comparisons. Tukey’s test was 




CHAPTER 5. DEVELOPMENT OF NANO-PARTICLE BASED 
IMMUNE MODIFIERS FOR THE TREATMENT OF TH2-
MEDIATED DISEASE 
5.1 Introduction 
Each immune process is the result of a single initial signal, such as recognition of a foreign 
antigen by an immune cell(260). The first line of defense is the innate immune system. Upon 
antigen recognition, macrophages and neutrophils mount an immune response, which results in 
the production of signaling cytokines and chemokines to signal to the local 
microenvironment(261). The second line of defense is the adaptive immune system. Naïve CD4+ 
T cells undergo clonal expansion and differentiation into distinct helper T (Th) cell subtypes, 
including Th1, Th2, and Th17 cells. Each subtype directs immune responses by producing 
specific cytokines to manage the immune response to pathogens(262). Upon contact with antigen, 
differentiated cells migrate to inflammatory sites and produce large quantities of effector 
cytokines.     
 The imbalance of T-cell subtypes is associated with the pathogenesis of autoimmune and 
allergic diseases.(263) Th1 and Th17 cell dysregulation is implicated in autoinflammation, 
whereas Th2 cells can drive allergic inflammation(10). Th2 cells express GATA-binding protein 
3 (GATA3), and secrete IL-4, IL-5, and IL-13. GATA3 is expressed in early T cell precursors and 
plays important roles throughout T cell development and maturation(264). Deletion of GATA3 in 
CD4+ T cells prevents their differentiation into Th2 cells, forcing a Th1 phenotype(265). 
Introducing GATA3 into differentiating Th1 cells induces the production and release of Th2 
cytokines(266). Thus, GATA3 acts as a master transcription factor for Th2 cell differentiation 
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and inhibition of the Th1 phenotype. Elevated GATA3 expression has been reported in a number 
of other chronic inflammatory disorders, including atopy and allergic asthma, and ulcerative 
colitis(267). Therefore, efforts have been focused on modulating the expression of GATA3(221). 
Asthma is a chronic respiratory illness that affects millions of Americans each year, 
resulting in billions of dollars of healthcare costs. Viral upper respiratory tract infections, 
allergens, and stress often trigger asthma symptoms and worsen inflammation (268).  The current 
backbone of asthma therapy is maintenance and control of symptoms.  If symptoms are not well 
controlled, additional asthma medications are added in a step-wise approach (269). 
Corticosteroids have long been used to manage asthma because they inhibit synthesis of key 
factors that cause and augment inflammation. Currently, inhaled corticosteroids are first line 
treatment for mild and moderate asthma, but severe asthma often requires oral corticosteroids to 
manage the disease. Oral corticosteroids have numerous side effects including hyperglycemia, 
weight gain, psychosis, and osteoporosis (270). Therefore, directed therapies to regulate these 
inflammatory signals without causing side effects are imperative for disease management.  
The most prevalent type of asthma (50% of patients) displays a Th2 endotype, which is 
characterized by an overabundance of Th2 cells that overexpress GATA3, causing a cascade in 
production and release of inflammatory cytokines such as IL-4, IL-5, and IL-13(271). Moreover, 
GATA3 has been found to be upregulated in biopsies and serum from patients with severe 
asthma, even while on oral corticosteroids (13), and has been shown to be expressed in resident 
lung cell types, such as mast cells (272), eosinophils (273), and airway epithelial cells (274). 
GATA3 blockade is a promising therapeutic strategy for the Th2 asthma endotype (275). 
Inhibiting GATA3 production by gene knockdown has been shown to suppress expression of 
cytokines and prevent the induction of airway hyperresponsiveness amongst other asthma 
symptoms (276). A recent phase I clinical trial demonstrated that administering GATA3-based 
inhibitors by inhalation can reduce the impact of an allergen challenge on FEV1 (forced 
expiratory volume in one second) in mild asthmatics (277). This study found that after treatment, 
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both the early and late asthmatic responses were attenuated, improving overall airway 
function(278). This emphasized the importance of GATA3 in regulating the asthmatic response. 
GATA3 has also been implicated in IBD, an autoimmune disease with similar pathogenic 
features of immune dysregulation. Inflammatory bowel disease (IBD) is comprised of 2 major 
disorders: ulcerative colitis (UC)(279) and Crohn’s disease (CD)(280). The exact etiology of IBD 
remains unknown, although studies have shown contributions from both the adaptive and innate 
immune systems. Several studies suggest the important roles of GATA3 in inducing and 
activating Th2 cytokine production. A recent study found increased expression of GATA3 in 
patients with active UC(267), and tested the efficacy of the same GATA3 based inhibitor in 
patients with UC. After rectal administration, this GATA3 inhibitor ameliorated colitis activity 
and led to suppression of Th2 cytokines(267). This work indicates the potential for GATA3 
blockade in colitis.  
Current therapies for UC, however, mainly focus on anti-TNF-a and alleviation of the 
acute phase immune response. Infliximab and Adalimumab, two of the most popular medications, 
are TNF-inhibiting antibodies(281). New developments in the treatment of inflammatory 
disorders include monoclonal antibodies, such as omalizumab and mepolizumab (282), that have 
specific inflammatory targets.  While these drugs specifically bind IgE and IL-5 respectively, 
they present a risk of anaphylaxis, a potentially life threatening condition (283). Recently, nucleic 
acid-based therapeutics have gained significant interest for their sequence-specific gene 
modulation. Six oligonucleotide-based drugs have been approved by the US Food and Drug 
Administration. Current oligonucleotides therapies have been approved for cytomegaloviral 
retinitis, familial hypercholesterolemia, Duchenne muscular dystrophy, and spinal muscular 
atrophy (SMA)(284, 285).  
Three gene regulation strategies are commonly utilized with oligonucleotide therapies, 
where the goal is to modulate disease intracellularly at the most upstream transcriptional level. 
These strategies are antisense oligonucleotides (ASO), which inhibit gene expression by binding 
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mRNA via Watson-Crick base pairing(286), catalytically active DNA enzymes (DNAzymes, Dz), 
which bind and cleave complementary RNA, and small interfering RNA (siRNA), which recruit 
the RISC complex to degrade RNA(287). However, major disadvantages to ASO delivery in vivo 
include nonspecific binding to proteins like fibroblast growth factor, and the upregulation of pro-
inflammatory factors(285). RNA interference (RNAi), such as small interfering RNA (siRNA) 
and microRNA (miRNA), requires the RNA-induced silencing complex (RISC) to induce mRNA 
degradation depending on sequence complementarity(288). While this technique exhibits higher 
efficiency compared to ASO, controlling intracellular bioavailability has proven difficult. Further, 
RNAi delivery and maintenance is difficult due to anatomical barriers, immunoreactivity, 
delivery challenges, and drug stability (289).  
Alternatively, Dzs represent a novel class of antisense molecules with several important 
properties that make them a strong candidate for gene regulation therapy. A well-known and 
widely studied Dz is the ’10-23’ Dz, described by Santoro and Joyce in 1997(290). It is an RNA-
cleaving DNA molecule consisting of a catalytic domain and 2 substrate binding arms. The 
binding arms hybridize to RNA sequences of interest, allowing the ’10-23’ Dz to accurately 
identify the RNA target in the cytoplasm, and the 15 base catalytic core cleaves at preferred 
purine-pyrimidine junctions. Though the exact mechanism of cleavage by the ’10-23’ Dz remains 
elusive, Liu et al. recently postulated that the ‘8-17’ Dz, a structurally similar Dz, likely adopts a 
V-shape fold consisting of a twisted DNA pseudoknot, forcing the RNA to bend and form a kink 
at the site of cleavage. This suggests a general acid-base mechanism of RNA catalysis(291). 
In 2008, Sel et al. manually scanned the GATA3 mRNA code and identified 70 potential 
Dzs in vitro, selecting specifically around purine-uracil junctions(292). The authors hoped to 
identify a Dz for targeting allergic and inflammatory disorders and identified a Dz, denoted as 
SB010. This therapy was an intracellular approach to regulate Th2 cell differentiation and control 
of subsequent cytokine transcription. Beyond the targeting capabilities of Th2 cells, GATA3 was 
recently shown to be expressed in epithelial cells, mast cells, basophils, and eosinophils(293). 
 87 
This suggests that GATA3 signaling may contribute to progression and perpetuation of the 
inflammatory response. Thus, intracellular disruption of GATA3 signaling is promising in 
reducing long-term inflammatory signals that damage the integrity of tissues. The authors 
validated each sequence using in vitro cleavage assays and verifying activity in acute and chronic 
allergic airway mouse models of asthma. Moreover, they compared the Dz to alternative 
antisense strategies, such as traditional antisense and siRNA, showing no differences in efficacy 
between the three. Notably, the Dz approach had the most potent effect on eosinophils.  
The authors note two important challenges in this technology. The first is off-target 
effects. The authors note that off-target effects are unfortunately common as a result of the 
interaction of foreign oligonucleotides with pattern recognition receptors, including toll-like 
receptors (TLRs), that respond to single- or double-stranded DNA, RNA, or CpG-motif-
containing DNA molecules(294, 295). Introducing a foreign piece of DNA is likely to stimulate 
the host’s innate immune system, resulting in an increased Th1 inflammatory component. This 
was observed using the traditional ASO approach in the study, which seemed to stimulate 
proinflammatory signals. 
The second challenge is efficacy of delivery, a challenge that has long plagued the 
antisense field with regards to in vivo applications. Oligonucleotide movement across the plasma 
membrane is challenging. Accordingly, clinical trials require 2 mg doses of oligonucleotides per 
patient per day, only showing moderate efficacy(296). In principle, improving the stability and 
delivery of Dzs will transform this new class of therapy.  
To overcome the challenges of delivering Dzs as gene regulation agents, we have 
developed and tested Dz-coated gold nanoparticles (DzNP) for gene regulation. This approach is 
based on the recent discovery by Mirkin and colleagues that showed that high density DNA 
arranged spherically around a ~10 nm nanoparticle leads to rapid recognition and uptake by over 
50 different cell types(297). These conjugates have passed phase 1 clinical trials for the treatment 
of inflammation in psoriasis (See Exicure press release http://www.exicuretx.com/). Importantly, 
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Mirkin and colleagues have shown that internalization is driven by caveolae-mediated 
endocytosis through binding of the scavenger receptor A (SRA) on the cell surface(298). The 
primary role of this receptor is the internalization of negatively charged oxidized LDL particles 
(that are ~20 nanometer in size). Building on this work, our lab demonstrated that 100 copies of 
Dz molecules immobilized onto a 14 nm gold nanoparticle through the 3’ terminus (but not the 5’ 
terminus) are highly active for mRNA knock down (299). We recently showed that DzNP can be 
used to knockdown TNF-a in a rat model of myocardial infarction(300). These DzNPs showed 
significant improvement in heart function following treatment with the active nanoparticle. In 
addition, DzNPs evade nuclease activity, as the conjugation to the gold nanoparticle creates a 
shell protecting the Dz. DzNPs showed minimal off-target effects and did not require the use of 
any transfection agents (300). Therefore, DzNPs offer an attractive approach for delivering 
functional nucleic acids.  
One concern with the DzNP strategy is the accumulation of gold metal within the cell. 
This is unlikely to be an issue because gold is one of the most biocompatible and least reactive 
metals known (301). Animal studies and human trials (rheumatoid arthritis (302, 303)  and 
psoriasis) with DNA-modified gold particles have been successful both in our lab and others.  
Further, it does not elicit an immune response from the surrounding environment when injected, 
making it non-immunogenic and an ideal carrier for functionalized oligonucleotides (304). This 
proposal will focus on developing DzNPs to target two inflammatory diseases, asthma and IBD. 
We will investigate optimal methods of GATA3 DzNP delivery to the lung, and its efficacy on 
reducing inflammation in asthma. In addition, we develop a combined method of treating 
inflammatory colitis using our improved GATA3 DzNP in combination with an anti-TNF-a 
DzNP. This technology has broad applications, as this work opens the door to targeting additional 








Figure 17. In silico Dz screen reveals 48 possible sequences.  
(A) Schematic illustration of the 10-23 Dz. Catalytic motifs are shown in blue. (B). Screening of a library 
of of 48 Dz sequences determined by in silico analysis for optimal GATA3 targetic sequence. 
Knockdown of GATA3 in a T47D breast cancer cell line was determined by RT-PCR. Red dotted line 
indicates level of SB010, a previously published GATA3 Dz. 18S was used as a housekeeping gene. 
Data is represented as mean + SEM. Statistical analysis was performed using one-way repeated measures 




5.2.1  In silico GATA3 DNAzyme screen  
The ’10-23’ Dz, described by Santoro and Joyce, is composed of a 15 
deoxyribonucleotide catalytic core flanked by two substrate recognition arms(290). In the 
presence of Mg2+, it will cleave any RNA substrate between an unpaired purine (A, G) and a 
paired pyrimidine (U, C) (Figure 17A). Its catalytic efficiency is determined by the rate of 
association between Dz and RNA substrate, and has been shown to have excellent catalytic 
efficiency(305). Because this heteroduplex formation determines the rate of catalysis, it is 
necessary to select an accessible cleavage site within the secondary structure of mRNA. 
Moreover, Dzs display strong substrate specificity and are thus sensitive to base-pairing 
mismatches in the recognition arm(306).  
We developed an algorithm for determining the optimal Dz sequence for any RNA 
sequence of interest. The RNA sequence of interest is scanned from 5’ to 3’ for AU or GU 
junctions. The free energy of hybridization is calculated for each binding arm to achieve optimal 
thermodynamic parameters for the DNA-RNA duplex. The algorithm then matches human with 
mouse gene variants and ranks each sequence by the free energy of the most stable secondary 
structure. Each sequence is then converted to a Dz sequence and the sequences are ranked based 
on human and mouse gene target base locations, left and right arm lengths, and secondary 
structure.  
Because the authors of the previously published GATA3 Dz only tested the first 70 hits 
around purine-uracil junctions, we anticipated that our algorithm would be able to identify their 
sequence, but likely also predict more optimal sequences. We performed this analysis for a 
GATA3 specific Dz, which resulted in a library of 48 possible additional hits. To validate these 
results, we tested each sequence by transfecting them in vitro, using a model breast cancer cell 
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line known to overexpress GATA3 (Figure 17B). RT-PCR analysis allowed for the isolation of 
three hits, 2093, 2251, and 2597, that had the highest level of knockdown over SB010, verifying 
that our algorithm can identify potent Dz sequences. These hits were selected for further analysis 





































 (A) Schematic showing synthesis of Dz-modified gold nanoparticles (AuNP). Thiolated 
DNA was mixed with 13 nm AuNP with gradual increase in salt concentration. (B) Dzs 
SB010, 2093, 2251, and 2597 were conjugated on AuNP (DzNP). T47D cells were 
treated with 5 nM of each DzNP construct and RNA was isolated after 48 hours. RT-PCR 
analysis for GATA3 implicated sequence 2251 with the highest potency. (C) 2251-AuNP 
was tested against soluble SB010 in T47D cells at 5 nM and 10 nM concentrations and 
GATA3 expression was quantified. GATA3 mRNA was significantly reduced at 10nM in 
just 24 hours. Statistical analysis was performed using one-way repeated measures 
ANOVA with Tukey post-hoc test. *p<0.05, **p<0.01, n=3. 





5.2.2 DzNPs regulation of GATA3 gene 
Dz sequences 2093, 2251, and 2597 showed improved efficacy over SB010 when tested 
in vitro following Lipofectamine transfection. To validate our DzNP technology, we tested the 
efficacy of each of the three sequences, 2093, 2251, and 2597, against SB010 when 
functionalized on gold nanoparticles (DzNPs). To achieve this, we purchased a 3’thiol modified 
2093, 2251, and 2597 and conjugated it to AuNPs. Approximately 100 copies of this Dz were 
functionalized onto a 14-nm gold via the salt-aging method previously published by Hill et al 
(307) (Figure 18A). A model breast cancer cell line, T47D, was used due to its overexpression of 
GATA3.  
Cells were incubated with 5 nM of each DzNP for 48 hours, and RT-PCR was performed 
to assess GATA3 expression. These data showed DzNPs 2251 and 2597 reducing GATA3 
mRNA expression, with 2251 consistently exhibiting the most potent knockdown of GATA3 
(Figure 18B). DzNP-2251 was compared to soluble SB010 without Lipofectamine to 
demonstrate the effects of DzNP against soluble Dz. This showed that the DzNP significantly 
enhanced potency of GATA3 knockdown in vitro (Figure 18C). These data suggest that DzNP-
2251 is a viable GATA3 therapeutic for inflammatory disease.  
5.2.3 Investigate DzNP-mediated delivery to the lungs of an animal model 
The airways are characterized into two vital regions: the conducting, or upper, airways 
and the lower respiratory region. The respiratory airway consists of respiratory bronchioles, 
alveolar ducts, and alveolar sacs. The lung encounters a number of foreign particles on a daily 
basis, which are either captured at the level of the upper airway on the mucocilliary surface or 
interact with the immune cells in the lower airway(308). At the level of the alveoli are a number 
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of immune cells, including alveolar macrophages, eosinophils, T-cells, and mast cells. Asthma is 
a common disease that is characterized by difficulty breathing and wheezing. Allergic asthma is a 
Th2-mediated disease, and a number of Th2-animal models of asthma have been established for 
the development of therapeutics(309). 
Delivering DzNPs to the lung poses several challenges. Directly targeting lung tissue by 
administering drug dropwise intranasally (IN) may lead to loss in the anatomical dead space, 
mainly in conducting airways. Nebulization (neb) may be a possible alternative, though it would 
require much higher volumes of drug to account for loss through the aerosolization process. 
Oropharyngeal (OP) administration has been proposed as an easy alternative to deliver different 
materials to the lungs. This method involves administering material to the trachea through the 
mouth (310). A recent study using silica particles showed less variability among animals and 
results in high uniformity of pulmonary distribution(311). Another study validated the use of OP 
induction over IN approaches, finding it to be as effective but without the disadvantages of 
administering the drug IN.(310) Further, a third study found that OP administration achieved 
similar dosing to that seen after IT administration.(312) 
To test this technique against the IN approach, we treated animals IN with 50 μl of 100 
nM Cy7-tagged AuNP (Figure 19C). Our collaborators administered the same Cy7-AuNP using 
their expertise in OP aspiration, experimentally dosing 100 μl at 5, 25, and 50 nM (Figure 19A). 
After 24 h, mice were sacrificed, and lungs were isolated for IVIS imaging analysis. Regions of 
interest were drawn around each lung, from which background was subtracted. Fluorescence 
intensity was calculated over the area of each lung to calculate integrated intensity and was 
plotted for OP (Figure 19B) and IN approaches (Figure 19D). Administration of AuNP at 25 
nM (2.7x107p/s) and 50 nM (3.1x107p/s) exhibit higher integrated intensities via the 
oropharyngeal approach than IN administration of 50 μl of 100 nM (~2.3x107p/s). Moreover, OP 
administration resulted in more homogeneous distribution at lower concentrations of DzNP. 
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Figure 19. Intranasal (IN) versus oropharyngeal (OP) administration of AuNP. 
(A) Cy7-AuNP was administered to C57bl/6 mice via OP technique. (A) Control mice were dosed with saline. 
Experimental animals were dosed at 55nM, 25nM, and 50nM. After 24h, lungs were isolated and fluorescence 
was visualized using IVIS. (B) Uptake was quantified by fluroescence intensity integrated over lung area. (C)  
50ul of 100 nM was administered into C57bl/6 mice and lungs were isolated after 24 hours for fluorescence 
visualization using IVIS. Control mice were dosed with 50ul of saline. (D) AuNP uptake was quantified by 
fluorescence intensity integrated over lung area. Data presented as mean ± SEM statistical analyses was 




5.2.4 Determine biodistribution of fluorescently tagged DzNP versus soluble Dz to 
elucidate the pattern of uptake in immune cells and resident lung cells.  
Potential biomedical application of NPs has been shown to be possible to the lungs via 
inhalation(84) or aspiration. (313) Because of the large epithelial surface area of both systems, the 
respiratory and GI tracts are some of the most promising for therapeutic nanoparticle technology. 
In the case of the lung, airborne particles deposit in different regions of the respiratory tract in a 
size dependent manner. Smaller particles, like nanoparticles, preferentially deposit in peripheral 
lung regions, like the alveoli. Depending on their size and composition, nanoparticles will interact 
with and become entrapped in pulmonary surfactants, which allows them to come into contact 
with pulmonary cells(314). Within the lung live a variety of immune cell populations, including 
phagocytic cells and antigen presenting cells. Thus, specific targeting to lung-resident immune 





Figure 20. Intranasal administration of ATTO647-AuNP Or ATTO647-soluble DNA results in 
differential uptake by immune and epithelial cells. 
(A) Experimental setup. Animals were dosed with equimolar concentrations of AuNP or soluble 
DNA. (B) After 24 hours, lungs were isolated and immune cell subtypes from the lung parenchyma 
were partitioned. Alveolar macrophages, eosinophils, and epithelial cells were gated based on 
control cells. Control (black), soluble DNA (red), and AuNP (blue). (C) Immune cell uptake of 
AuNP or soluble DNA represented by histogram. 
 99 
In order to elucidate the efficacy of DzNP action, it is necessary to understand their 
biodistribution. GATA3 is traditionally thought to be expressed in the Th2 population of T-cells 
in the perpetuation of the immune system. However, Th2 inflammation is mediated by a number 
of other cell types. Moreover, GATA3 is expressed in a number of other cells, including mas 
cells, eosinophils, and basophils(293). Interestingly, studies have shown that the major site of 
GATA3 expression in the lower airways is the bronchial epithelium (316). Understanding the cell 
uptake profile of DzNPs not only confers a potential mechanism of action of GATA3 
knockdown, but also provides information for the rational design of future therapeutic targets in 
inflammation. Thus, due to the expansive surface area covered by epithelial cells, we hypothesize 
that epithelial cells and macrophages will show the highest uptake of DzNPs. Understanding 
which cell type is mediating inflammatory regulation will be crucial for future development of 
therapeutically active DzNPs. 
To visualize soluble DNA or tagged AuNPs in specific immune cell populations, we 
selected ATTO647 as a fluorescent dye in the red spectral region to avoid macrophage 
autofluorescence in the fluorescein channel. Soluble DNA and AuNP were tagged with 
ATTO647 and resuspended in phosphate buffered saline (PBS) for delivery to mice. Wild-type 
C57bl/6 mice were anesthetized using isoflurane and administered either 100 nM AuNP or 10 μM 
soluble DNA (Figure 20A). Importantly, these concentrations were selected to match the 
concentration of DNA in each dose. After 24 h, mice were sacrificed, and lungs were digested to 
stain for flow cytometry. Alveolar macrophages (AMs), eosinophils, and epithelial cells were 
partitioned and nanoparticle versus soluble DNA uptake was measured (Figure 20B,C). Because 
these were wild-type mice, eosinophil counts were lower than would be expected in an inflamed 
model of asthma. Interestingly, we observed high uptake of soluble DNA in alveolar 
macrophages over AuNP. This was expected, as AMs are the primary phagocytes of the immune 
system(317). Epithelial cells also take up high levels of soluble DNA but seem to endocytose a 
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fraction of AuNP as well. This is significant, as in an inflamed lung, the tight junctions between 











Figure 21. Intranasal administration of ATTO647-AuNP or ATTO647-soluble DNA following 
HDM sensitization results in differential cell uptake. 
(A) HDM-sensitized mice were treated IN with ATTO647-AuNP or ATTO647-soluble DNA d10-
14. (B) Partitioning of immune cell subtypes in the bronchoalveolar lavage (BAL) and lung 
parenchyma of control (green), AuNP (blue), and soluble-DNA (red) treated groups. Intravenous 
αCD45 Ab staining was used to differentiate between migratory immune cells and resident lung 
immune cells. (C) Graphed total immune cell uptake of AuNP or soluble DNA between BAL and 
lung. Data presented as mean ± SEM. Statistical analyses was performed using one-way ANOVA 






To investigate the role of inflammation in DzNP uptake, we performed a similar 
experiment with HDM sensitization. In this case, we treated animals intranasally with 25 μg 
HDM daily for 3 weeks. During the last week, we co-administered 50 μl of 100 nM ATTO647-
AuNP or 50 μl 10 μM soluble DNA (Figure 21A). Mice were sacrificed, and cells were 
partitioned for flow cytometry, staining for AMs, neutrophils, CD103+ DCs, eosinophils, CD4+ 
T-cells, and CD8+ T-cells. In order to identify which immune cells were resident to the lung, or if 
they migrated in as a response to HDM, cells were stained with a CD45.2 antibody. CD45.2+ 
intravenous staining implies the cells are migratory immune cells. This information allows us to 
identify whether DzNP is largely taken up by the resident lung cells or by cells recruited to the 
site of inflammation. 
Surprisingly, we observed a statistically significant increase in CD8+ T-cells uptake of 
fluorescently tagged DzNP in the lungs versus soluble DNA. Similar trends were observed in 
CD103+ DCs, and CD4+ T-cells (Figure 21B).  In this case, AMs actually showed consistent 
uptake of both soluble DNA and AuNP, conflicting with our observed results in non-HDM 
sensitized animals (data not shown). Neutrophils and eosinophils did not significantly 
phagocytose either AuNP or soluble DNA. The difference in uptake between resident lung cells 
versus migrating cells was also intriguing. Most of the cell uptake was observed in resident cells, 
suggesting that the mechanism of action of DzNPs may be caused by these cells in particular. 






















Figure 22. DzNP 2251 reduces airway resistance and Th2-related cytokines in mouse model of asthma. 
(A)  Two groups were sensitized to HDM for three weeks under isofluorane anesthesia. Two groups 
were not given HDM. DzNP was administered intranasally to HDM-sensitized and a group of wild-type 
mice during week 3. (B) After 21 days, animals were anesthetized using ketamine/xylazine and airway 
resistance was measured using a SCIREQ Flexivent. Data presented as mean ± SEM statistical analyses 





5.2.5 Determine 2251-DzNP efficacy in a Th2-mouse model  
To test the efficacy of our therapy, we prepared 100 nM solutions of DzNP-2251, our 
GATA3 DzNP, resuspended in PBS for intranasal delivery. Animals were administered either 
HDM or vehicle for 21 days to emulate chronic asthma. The 2251-DzNP alone was administered 
in two groups: in an HDM sensitized group and an unsensitized group to determine the effects on 
asthmatic mice, as well as to determine if 2251-DzNP alone had an immunostimulatory effect 
(Figure 22A). On day 21, mice were anesthetized using a combination of ketamine and xylazine 
to simultaneously induce anesthesia, as well as paralyze the diaphragm to accurately measure 
pulmonary resistance. Each trachea was cannulated, and mice were transferred to the FlexiVent 
(SCIREQ) system for forced oscillation measurement. Airway resistance was plotted against 
increasing methacholine concentrations. HDM-sensitized mice experienced the highest airway 
resistance, while control mice did not have large increases in resistance.  
HDM-sensitized mice experienced the highest airway resistance, while control mice did 
not have large increases in resistance. Control versus HDM mice showed a significant increase of 
airway resistance. DzNP 2251 alone did not seem to result in augmented levels of airway resistance, 
though the baseline was mildly higher than control animals. Remarkably, DzNP 2251 significantly 
reduced airway resistance in HDM treated mice when comparisons were made between HDM and 
HDM+2251 treated groups. 
 
5.2.6  Determine efficacy of orally delivered DzNP using an alginate hydrogel delivery 
method.  
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 To test particle release following nanoparticle encapsulation and delivery, we modified 
AuNP with Cy7-tagged DNA, which permits visualization in the colon using IVIS imaging. 
C57bl/6 mice were administered 200 nM Cy7-tagged AuNP in a 10 mg/ml alginate solution, 
followed by a second gavage of CaCl2 to initiate gelation in the stomach, as per a previously 
published protocol by Laroui et al(316). Levels of fluorescently tagged AuNP were visualized 
using IVIS imaging. Control mice were given alginate alone followed by CaCl2 double gavage.  
Mice were sacrificed after 6, 24, and 48 hours, and the colon was isolated and flushed 
with PBS to remove any contaminating fecal signal. Cy7-fluorescent signal was visualized using 
IVIS, and images were taken of colons in duplicate (Figure 23A). Regions of interest were 
drawn around each colon, and background signal was subtracted. Signal was integrated over the 
length/area of each colon and normalized to control. Overall integrated intensity was calculated 
and plotted (Figure 23B) to visualize time points when the highest DzNP release had occurred. 
These data suggested that the highest levels of DzNP accumulated in the colon around 6 h, with 
signal still visible around 24 h. These results validated that our method of oral delivery was 





















Figure 23. DzNP localization to the colon following oral delivery. 
(A) 200 nM Cy7-tagged AuNP in 10mg/ml alginate solution were delivered orally to mice, followed by 
second gavage of CaCl2. Mice were sacrificed after 48 hours, 24 hours, and 6 hours. The colon was 
isolated and imaged using IVIS. (B) Regions of interest (ROIs) were drawn around each colon and 
compared to background. Integrated intensity (p/s) was calculated taking into account fluorescent 
intensity per area of colon. Each colon was normalized to control (no fluorescent particle). Data 
presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Tukey’s 













5.2.7 Evaluate DzNP distribution within the intestinal villi, characterizing the role of 
intestinal epithelial cells (IECS), gut-associated lymphoid tissue (GALT), and 
immune cells in particle uptake. 
Because of the absorptive nature of the large intestine, it is necessary to understand the 
distribution profile of DzNP. We sought to take advantage of the endocytic uptake mechanisms of 
intestinal epithelial cells (IECs), gut-associated lymphoid tissue (GALT), and immune cells 
because GATA3 is traditionally thought to be expressed in the Th2 population of T-cells in the 
perpetuation of the immune system. However, the intestine epithelial cells (IECs) play a 
significant role in the immune response, and due to their surface area, likely take up a large 
number of DzNPs. The immune cells in the gastrointestinal tract are also highly active and 
constantly coming into contact with luminal agents. GALT includes Peyer’s patches and 
mediastinal lymph nodes, which are hubs for T- and B-cell interactions and communication. We 
hypothesize that DzNP will likely be found in highest concentration in IECs cells. 
We first evaluated uptake in a few different immune cell subtypes isolated from intestinal 
tissue to determine whether immune cells can take up the nanoparticles after encapsulation and 
release from alginate hydrogels. We tagged AuNP with ATTO647, a fluorescent dye, and mixed 
the AuNP with alginate solution. Animals were gavaged first with ATTO647-AuNP or vehicle, 
followed by CaCl2 to induce gelation in the stomach. After 24 hours, they were sacrificed, the 
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colon tissue was isolated, and immune cells were isolated for flow cytometry. Nanoparticle 
uptake was tested in CD4+ T-cells, (Figure 24A), CD8+ T-cells (Figure 24B), macrophages 
(Figure 24AC), and neutrophils (Figure 24D). Gates were set based on vehicle-treated control. 
Interestingly, all four cell types showed significant signal of fluorescently tagged AuNP when 
compared to control animals. This indicates that the gastrointestinal immune cells take up much 
higher levels of AuNP than we observed in the lung. Neutrophils showed the highest uptake of 
AuNP, followed by macrophages. Remarkably, CD4+ T-cells showed the highest levels of 
adaptive cell uptake over controls, in contrast to the high levels of CD8+ T-cells that we found to 
































Figure 24. Alginate hydrogel delivery of DzNPs for GI cell uptake 
ATTO647-tagged nanoparticles in an alginate hydrogel solution were gavaged, followed by a CaCl2 
chelating solution. Mice were sacrificed after 24h and GI cells were isolated and stained for flow 
cytometry. Cell uptake was assessed by gating against control (untreated) cells in CD4+ T-cells (A), 
CD8+ T-cells (B), macrophages (C), and neutrophils (D). 
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5.2.8 Evaluate efficacy of orally delivered GATA3 and TNF-a DzNPs in a mouse model of colitis.  
Oral drug delivery is the most attractive pathway for chronic debilitating gastrointestinal 
diseases, such as UC and Crohn’s disease. Conventional approaches have many drawbacks, 
including inefficacy, ineffective drug release, and limited targeting to inflamed areas. 
Furthermore, developing a drug that can effectively bypass the acidity of the stomach would be 
ideal. Current therapeutics for UC include biologics, with anti-TNF-a monoclonal antibodies 
being the most popular. These are widely used for their ability to alleviate immediate 
inflammation, but unfortunately, do not exhibit long-term effects. Based on the promise of our 
GATA3 DzNP and a recent publication highlighting the promise of GATA3 therapy in UC, we 











Figure 25. Hydrogel delivery of GATA3 and TNF DzNPs alleviates inflammation in DSS 
colitis mouse model. 
C57bl/6 mice were treated for 11 days with either GATA3 alone, TNF alone, or a combination 
of the two in a DSS mouse model of colitis. Control mice received a DzNP with a scrambled 
Dz sequence. (B) Disease activity index (DAI) shows a combined therapeutic of the two 
DzNPs results in a statistically significant improvement in relative disease. Data presented as 
mean ± SEM statistical analyses was performed using two-way repeated measures ANOVA 
with Tukey’s post-hoc test, *p<0.05, n=5. 
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Mice were administered alginate encapsulated DzNP for 5 days before beginning DSS. 
Animals were either treated with a scrambled DzNP (control), TNF-α DzNP alone, GATA3 
DzNP alone, or a combination of TNF-α and GATA3 DzNPs (Figure 25A). On day 5, DSS was 
added to the water of each group. Hydrogel polymerization was achieved by double gavage, 
meaning that the alginate-DzNP solution (200 nM DzNP in 10 mg/ml alginate) was gavaged first, 
followed by a second gavage of CaCl2 chelating solution for hydrogel formation in the stomach.  
On day 11, DzNP treatment was stopped while mice continued DSS until day 13. The 
mice were given 5 days to resolve following cessation of DSS. Weight, stool consistency, and 
blood in stool were measured every day from day 0 to day 18. These parameters allowed for the 
calculation of disease activity index (DAI), which is a research tool that defines severity of 
disease. DAI is the gold standard for assessing disease index in animal models of colitis.(318) 
DAI analysis indicated that TNF-α and GATA3 DzNPs alone did not cause any major 
improvements in UC. However, the combination of both DzNPs resulted in a statistically 
significant improvement of disease (Figure 25B). This was confirmed by histology scoring by a 











Hydrogel delivery of GATA3 and TNF DzNP alleviates inflammation in a DSS model of colitis. 
C57bl/6 mice were treated for 11 days with either GATA3, TNF, or a combination of the two 
DzNPs. Control mice received a scrambled DzNP. DzNPs were mixed in alginate and delivered via 
oral gavage, followed by a second CaCl2 solution to form a hydrogel in the stomach. (A) 
Representative colon gross pathology from mice sacrificed after treatment. (B) Histological scoring 
by a blinded pathologist. Data presented as individual values ± S.E.M. Statistical analyses were 




We developed a DNAzyme-based therapeutic for the treatment of chronic inflammatory 
disorders, such as asthma and IBD. We first performed a screen in vitro using a model cell line 
that overexpresses GATA3. After selection of a promising GATA3 Dz sequence, we conjugated 
it to AuNPs to confirm its efficacy over current GATA3 therapeutics. Next, we hypothesized that 
the selected DzNP would be an effective method of regulating GATA3 in vivo, leading to 
reduction of Th2-specific measures of disease.  
Multiple mouse models of allergic airway inflammation have been established to 
investigate different questions in a Th2 model of disease.(319) These models include the house 
dust mite (HDM), ovalbumin, molds and cockroach antigen(320). HDM sensitization is becoming 
increasingly common and is one of the most clinically-relevant models, reflecting the allergic 
response and respiratory changes in 85% of asthmatic patients(321). Observations of airway 
remodeling, such as goblet cell hyperplasia and collagen deposition, are usually observed in 
chronic HDM models.(322) Airway inflammation and enhanced methacholine responsiveness are 
observed as a result of this experimental model of asthma. No therapy to date has shown efficacy 
in reversing airway remodeling, though treatments exist for airway hyperresponsiveness and 
symptom management. Therefore, any therapeutic for long term therapy should assess their 
effects on collagen deposition and airway remodeling. Thus, we utilized an HDM-model of 
asthma with intranasal administration of therapeutic because of its clinical relationship to Th2-
mediated asthma. Interestingly, when we analyzed DzNP biodistribution, we observed high 
uptake of soluble DNA in alveolar macrophages over AuNP. This was expected, as AMs are the 
primary phagocytes of the immune system(317). Epithelial cells also take up high levels of 
soluble DNA but seem to endocytose a fraction of AuNP as well. This is important, as in an 
inflamed lung, the tight junctions between the epithelial cells become leaky, and a larger number 
of immune cells are recruited. Moreover, when we assessed DzNP overall efficacy using 
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pulmonary function tests (PFTs), we observed a reduction airway resistance in mice that had been 
treated with both 2251-DzNP and HDM over HDM alone. This supported our hypothesis that 
DzNP-treatment would alleviate Th2 disease. 
Thus, we aimed to confirm our findings in another Th2 mouse model of inflammation. 
Inflammatory bowel disease (IBD) is comprised of 2 major disorders: ulcerative colitis (UC)(279) 
and Crohn’s disease (CD)(280). The exact etiology of IBD remains unknown, though studies 
have shown contributions from both the adaptive and innate immune systems. Inflammatory 
stimulation from the adaptive immune system includes mucosal inflammation caused by T-cell-
derived cytokines. Interestingly, different T-cell subtypes are at play in CD versus colitis. Studies 
have shown increased levels of Th1 cytokines in CD, such as interferon-g (IFN-g) and tumor 
necrosis factor (TNF). In UC, however, patients exhibit elevated levels of Th2 cytokines, 
including IL-4, (323)IL-5 and IL-13(324, 325). Both diseases have been shown to produce 
increased levels of IL-6(326) and a cytokine more associated with Th17 T-cells, IL-17A.(327) 
 In the mucosal immune system, several studies suggest the important roles of GATA3, 
signal transducer and activator of transcription (STAT)-6, c-Maf, and others in inducing and 
activating Th2 cytokine production. STAT6 induces GATA3 via activation of GATA3 
promoters(328). Interestingly, GATA3 itself has been shown to induce its own expression, either 
directly via autoregulation or indirectly via Dec2, a transcription factor(325, 329). This suggests 
that GATA3 transcription leads to stabilization in GATA3 expression in immune cells. GATA3 
has been shown to inhibit STAT4 and subsequently, IFN-g expression, thus suppressing the Th1 
immune response.(330)   
In mouse models, conditional knockdown of GATA3 prevented the induction of 
oxazolone colitis, a murine colitis model(331). Recent clinical work has shown increased 
expression of GATA3 in pediatric UC. (332) Another study identified increased expression of 
GATA3 in mucosal T lymphocytes in patients with active UC(267). This study characterized 
GATA3 expression primarily in gut T-cells and epithelial cells. Further, this group tested the 
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efficacy of SB010, a GATA3 Dz previously shown to have efficacy in allergic asthma, in patients 
who had UC. After rectal administration, GATA3 blockade ameliorated colitis activity and led to 
suppression of Th2 cytokines. This work indicates the potential for GATA3 blockade in colitis.  
Current therapies for UC, however, mainly focus on anti-TNF-a and alleviation of the 
acute phase immune response. Infliximab and Adalimumab, two of the most popular medications, 
are TNF-inhibiting antibodies. Even in the SB010 trial, the authors deliver their drug intrarectally, 
which would pose future problems with patient compliance. Procedures such as enemas that are 
often used to target drugs to the colon are difficult, and can lead to complications locally in the 
intestine, including bleeding or perforation. Thus, we proposed designing a method of treating 
colitis using our improved GATA3 DzNP in combination with an anti-TNF-a DzNP. As 
described above, we previously published successful use of a TNF-a DzNP therapy for 
myocardial infarction. Local injection of DzNP yielded TNF-a knockdown of 50%, and 
subsequent reduction of inflammation with improved cardiac function(300). By combining the 
two DzNP therapies we can therefore target both the acute immune response (TNF-α), and a 
long-term inflammatory pathway (GATA3).  
As an alternative to rectal delivery, we chose to deliver these nanoparticles in an alginate 
hydrogel formed by giving a double gavage of alginate/DzNP followed by CaCl2 as previously 
described(333). Oral delivery to the intestine is challenging because of the acidic pH of the 
stomach, so oral drugs are often given frequently, or in high doses to circumvent degradation, 
which may lead to an increased number of side effects. By targeting both GATA3 and TNF-a 
specifically in the colon, we hypothesized that we would see resolution of symptoms of colitis. 
We utilized flow cytometry to confirm that the double gavage method would deliver DzNPs to 
the Gi tract. Indeed, we observed intracellular uptake within the colon. Moreover, we confirmed 
uptake of nanoparticles in both innate and adaptive immune cell populations by flow cytometry.  
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We next aimed to test dual delivery of GATA3 and TNF in a mouse model of colitis. 
Because part of our therapeutic aimed to modulate GATA3, a transcription factor, we selected to 
administer DzNP for 5 days before beginning the DSS colitis model. This would ensure that we 
were modifying how the T-cells differentiate into their future roles and subsequently recruit more 
inflammatory cells, while still targeting the acute phase reactors, such as TNF- α. Thus, we 
delivered GATA3 treatment alone, TNF alone, and dual GATA3 and TNF via double gavage. We 
did not see any changes in either therapeutic alone, but combined delivery of both factors resulted 
in significantly lower scores of disease activity than control. These findings were confirmed by 
histological scoring by a blinded pathologist.  
The reduction in severity of colitis symptoms in dual TNF-α and GATA3 treated mice was 
expected, but we did not expect the degree of disease amelioration observed in these mice. This 
introduces a number of questions. The mechanism of action of this dual therapy is intriguing, 
indicating there is potential synergy at play. It is thus necessary to pursue molecular analysis of 
Th1 and Th2 cytokines to elucidate which pathways are contributing to the response.  It is also 
interesting to note that TNF-α and GATA3 therapies alone did not perform better than control, 
potentially suggesting that the formation of the alginate hydrogel confers protection of the 
intestinal epithelium against DSS. 
While DSS is a viable model of colitis, it is more of a general model of inflammation in the 
colon. To further investigate these results, it will be necessary to follow these studies up with 
another mouse model of colitis, such as the TNBS models of colitis. Since TNBS is a more Th2 
skewed model of colitis, it will be interesting to note if the trends are the same or are as 
pronounced as the DSS model. Further, future directions should examine the levels of Th1 and 
Th2 cytokines known to be upregulated in colitis, such as IL-4, IL-5, IL-6, KC, to better 
understand how the DzNPs are ameliorating disease. Ideally, the results from these studies will 




5.4.1 In silico screen of DzNP 
T47D cells were brought to 80% confluency on 24-well plates and incubated for 48 hours 
with Lipofectamine RNAiMAX in 50 ul total volume along with fresh OPTI-MEM. siGATA3 
(GATA3 siRNAs, ThermoFisher) was used as a positive control. After 48 hours, cells 
were trypsinized and total RNA was extracted using RNeasy Mini Kit (Qiagen). Purified RNA 
was eluted into RNAse-free water and stored at -80C until use. RNA concentration and 260/280 
ratios were determined using a Nanodrop UV spectrophotometer (Thermo Scientific). Total RNA 
was reverse transcribed to cDNA using iScript cDNA Synthesis Kit (Bio-Rad) following the 
manufacturer’s protocol. Target gene expression was quantified using GATA3 primer 
(Mm00484683_m1) and normalized to 18S. cDNA was amplified with TaqMan Universal PCR 
Master Mix (Applied Biosystems).   
 
5.4.2 IVIS imaging 
100 nmoles of amine-T20-SH DNA were functionalized with 300 ug of Cy7 
dissolved in DMSO using 0.1 M sodium bicarbonate. The Cy7-T20-DNA was filtered 
through a P2 bead and added to 23 mls of AuNPs (4 nM) overnight. The Cy7-T20-
AuNPs were salted in 20-minute increments up to 0.7 M, then were washed to remove 
excess salt and DNA, as per previously described protocol. The DzNPs were 
administered to mice for flow cytometry at 3 concentrations: 5 nM, 25 nM, and 50 nM. 
Control animals were given intranasal administration of PBS.  
Care of experimental animals was performed in accordance with Emory University 
IACUC guidelines. Mice were anesthetized using isofluorane (3%) for 3 minutes. Mice 
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were administered Cy7-AuNP either via intranasal or oropharyngeal method. After 24 
hours, lungs were isolated and utilized for ex vivo IVIS imaging. Radiance emitted from 
the chest of mice was quantified using Living Image software (Perkin Elmer Inc. Boston, 
MA, USA). Data were expressed as integrated intensity (ps( over the baseline 
fluorescence of each mouse. 
5.4.3 Biodistribution of AuNP in the lung 
100 nmoles of amine-T20-SH DNA were functionalized with 300 ug of 
ATTO647 dissolved in DMSO using 0.1 M sodium bicarbonate. The ATTO647-T20-
DNA was filtered through a P2 bead and added to 23 mls of AuNPs (4 nM) overnight. 
The ATTO647-T20-AuNPs were salted in 20-minute increments up to 0.7 M, then were 
washed to remove excess salt and DNA, as per previously described protocol. The 
remaining DzNPs were administered to mice for flow cytometry. Soluble amine-T20 SH 
DNA-Cy7 was separately utilized as a control. 
Mice were anesthetized using isofluorane (3%) for 3 minutes. Following 
anesthesia, each mouse was given 50 ul of ATTO647-T20-AuNP dropwise via a 
pipette. After 24 hours, mice were sacrificed and lungs were isolated and homogenized 
for flow cytometry, as previously described(334). The following panel was utilized to 
































5.4.4 Th2 animal model of asthma 
Care of experimental animals was performed in accordance with Emory University 
IACUC guidelines. Mice were administered either 2.5mg/ml HDM or vehicle for 21 days to 
emulate chronic asthma. The 2251-DzNP alone was administered in two groups: in an HDM 
sensitized group and an unsensitized group to determine the effects on asthmatic mice, as well as 
to determine if 2251-DzNP alone had an immunostimulatory effect. On day 21, mice were 
anesthetized using a combination of ketamine and xylazine to simultaneously induce anesthesia, 
as well as paralyze the diaphragm to accurately measure pulmonary resistance. Each trachea was 
cannulated, and mice were transferred to the FlexiVent (SCIREQ) system for forced oscillation 
measurement. Measurements included resistance, compliance, and elastance(335). To measure 
airway hyperreactivity(336), mice were challenged with increasing concentrations of aerosolized 
methacholine generated by an in-line nebulizer, starting from saline, 6.25, 12.5, 25, 50, and 100 
mg/ml (Figure 22B). Airway resistance was plotted against increasing methacholine 
concentrations. HDM-sensitized mice experienced the highest airway resistance, while control 
mice did not have large increases in resistance. 
5.4.5 Oral gavage and gastrointestinal flow cytometry 
100 nmoles of amine-T20-SH DNA were functionalized with 300 ug of 
ATTO647N dissolved in DMSO using 0.1 M sodium bicarbonate. The ATTO647-T20-
DNA was filtered through a P2 bead and added to 23 mls of AuNPs (4 nM) overnight. 
The ATTO647-T20-AuNPs were salted in 20-minute increments up to 0.7 M, then were 
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washed to remove excess salt and DNA. The remaining DzNPs were administered to 
mice for flow cytometry.  
5.4.6 In vivo DSS colitis mouse model 
Dextran sodium sulfate colitis (36000-50000 MW; MP Biomedical) was induced 
by administering 3% w/v in autoclaved water and allowing mice to drink ad libidum for 9 
days. Treatment groups (n=5) of DSS+control, DSS+TNF, DSS+GATA3, and 
DSS+TNF+GATA3 were administered via an oral gavage needle. Total volume was 
200ul. Mice were fasted overnight, then gavaged once daily for 5 days prior to induction 
of DSS. After starting DSS, mice were gavaged daily for another 6 days of DSS in the 
water supply. Disease activity index (DAI) was scored daily. DAI was calculated as the 
sum of the stool consistency scores (0:hard, 2: soft, 4:diarrhea), fecal occult blood 
(0:negative, 2:positive, 4:macroscopic), and weight loss (0:<1%, 1:1-5%, 2:5-10%, 3:10-
20%, 4:>20%). Fecal occult blood was calculated using Hemoccult Sensa (Beckman 
Coulter). DzNP treatment and DSS administration, mice were sacrificed, and colons were 
measured, then harvested and preserved as swiss rolls in paraffin for histology. 
5.4.7 Tissue Harvest and Flow Cytometry 
To collect samples for flow cytometry analysis, mice were euthanized via CO2 
asphyxiation and digested according to previously described protocol(259). Small intestine was 
isolated and flushed with cold PBS. Tissue segments were placed in extraction media (Hank’s 
Buffered Salt Solution, Millipore Sigma, 5 mM EDTA, 10 mM HEPES) and incubated for 15 
minutes while shaking at 37ºC. 
After incubation, the supernatant containing epithelial cell and intraepithelial 
lymphocytes was isolated using a 100 µm cell strainer. The remaining small intestinal tissue was 
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placed into 6 ml of digestion media (RPMI, Millipore Sigma, 1 mg/ml collagenase V) and 
vigorously shaken at 37ºC. The digested tissue was filtered through a 100 µm strainer and rinsed 
with RPMI containing 10% FBS. The four solutions, containing epithelial cells, small intestine, 
spleen, and Peyer’s patches, were centrifuged at 800 x g for 5 minutes at 4ºC. The cell pellet was 
resuspended in 1 ml RPMI containing 2% FBS. Single cell suspensions were stained for flow 
cytometry analysis using standard methods and analysed on a BD LSRII (BD Biosciences).  
The antibodies used for identifying cell populations were: PerCP conjugated CD3 
(BioLegend), BV605 conjugated CD4 (BioLegend), BV785 conjugated CD8, APC-Cy7-
conjugated Ly6G (BioLegend), BV510-conjugated CD11b (BioLegend), BV711-conjugated PE- 
APC conjugated F4/80 (BioLegend). 
5.4.8 Statistical analysis  
All statistical analyses were performed using Graphpad Prism version 7.0d (La Jolla, 
CA). Results are reported as mean ± standard error of the mean (SEM). For grouped analyses, 
one-way ANOVA with Tukey’s post-test was used for multiple comparisons. Tukey’s test was 
used when comparing paired samples, while Bonferroni’s test was employed when comparing 












CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Overall summary 
 The work presented in this thesis represents a contribution to the fields of biomaterials 
and regenerative medicine by demonstrating the use of dimensionality reduction techniques for 
the elucidation of cellular heterogeneity of the immune response to stimulation and treatment 
with immunomodulatory hydrogels. In particular, this work explores the role of both innate and 
adaptive immune systems, and their respective roles in the processes of healing or immune 
resolution. This work expands the understanding of the relationship between pro-regenerative 
innate and adaptive immune cells and identifies methods by which we can manipulate these 
processes and pathways. The enhanced recruitment of anti-inflammatory, and inhibition of pro-
inflammatory cellular subsets can be manipulated for the reduction of disease processes, such as 
in IBD or in acute or chronic wounds. 
 In Aim 1, we explored the ability to target the recruitment of pro-regenerative cells from 
both the innate and adaptive immune systems. In particular, we engineered a hydrogel for the 
release of both anti-inflammatory factors IL-10 and AT-RvD1 in vivo. Increased evidence 
suggests that the promotion of healing actually involves a reduction in pro-inflammatory cell 
subtypes, such as M1 macrophages, and the recruitment of pro-resolving immune cell subtypes. 
In fact, dysregulation of the shift between M1 and M2 macrophages is seen in chronic 
wounds(337-339). Chronic wounds have an increased and prolonged inflammatory stage, with 
high levels of pro-inflammatory cytokines in wound fluid. (29, 339, 340). By combining IL-10 
with AT-RvD1, we aimed to deliver the major cytokine involved in the transition between the 
inflammatory to proliferative phase of inflammation, IL-10, as well as a lipid mediator previously 
shown to induce resolution of inflammation (181, 341). Combined delivery of the two factors 
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allowed for synergy of both factors, by promoting the recruitment of M2 macrophages, IL-10 
DCs, and reducing M1 macrophage recruitment. Moreover, because we were interested in a big 
picture view of immune cell recruitment, the usage of SPADE allowed us to visualize the high 
dimensional dataset into a 2D “tree” that elucidated the cellular heterogeneity in response to 
treatment. The trees developed by SPADE not only validated our findings but were instrumental 
in helping us identify a CD8+ IL-10 expressing cell that only seemed to be present in dual 
hydrogel samples. Taken together, these results indicate that local immunomodulation using 
combined delivery of therapeutic factors can influence the immune milieu at the site of injury. 
Furthermore, using dimensionality reduction techniques such as SPADE allow for the 
development of a big-picture view of all immune cells involved; crucial data that may have been 
missed by traditional flow cytometry gating.  
 In aim 2, we investigated the immune response at the single-cell level to AvrA 
microparticles. We previously identified AvrA, used by Salmonella, as an enzyme with anti-
inflammatory and anti-apoptotic effector functions (9, 218). Autoimmune disorders, like IBD, are 
a potential target for novel therapeutics, particularly because 30% of IBD patients do not respond 
to the standard-of-care, anti-TNF therapy(342). Moreover, the current therapies for IBD have a 
range of side effects that lead to poor compliance from patients. Because Salmonella utilize a type 
III secretion system to deliver AvrA, we previously developed a protein nanoparticle 
encapsulating AvrA for intracellular targeting(227). We have also established alginate and 
chitosan microparticles for oral delivery of AvrA(8). In this aim, we characterized the effects of 
the immune response at the single-cell level using flow cytometry. We observed reduced 
neutrophil infiltration in the Peyer’s patches, the small masses of lymphatic tissue within the 
small intestine. We also found decreased numbers of CD4+ cells in the Peyer’s patches, and 
reduced CD8+ T-cells in the intraepithelial lymphocyte population following AvrA microparticle 
treatment in LPS stimulated mice. The effects of AvrA only seemed to lead to a local immune 
modulation, as both innate and adaptive immune cell counts were unchanged in the spleen after 
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LPS stimulation. Interestingly, macrophage numbers were unaffected in the small intestine. 
Future directions must focus on further parsing out the macrophage phenotypes, using 
dimensionality reduction techniques such as SPADE to determine the pseudotime trajectory of 
macrophage maturation and differentiation. SPADE was instrumental in uncovering the 
activation status of CD8+ T-cells in this aim. SPADE analysis showed reduced CD8+ Ly6C+ T-
cells in AvrA treated groups, which led us to investigate the phenotype of this cell subset. Further 
investigation elucidated a CD8+ Ly6C+ CD44+ population which was modulated by AvrA 
therapy. CD44 is an activation-associated surface marker on T-cells, with CD44hi cells having an 
effector phenotype(343). CD8+ CD44high Ly6C+ cells have also been suggested to have memory-
type phenotypes(256). These data suggest local effects on both the innate and adaptive immune 
system that may be further elucidated with more extensive models of gastrointestinal 
inflammation. 
 In aim 3, we developed a DNAzyme-based therapeutic for the treatment of chronic 
inflammatory disorders, such as asthma and IBD. We hypothesized that the selected DzNP would 
be an effective method of regulating intracellular GATA3, leading to reduction of Th2-specific 
cytokines. We observed a reduction in inflammation in both a Th2-mouse model of asthma, as 
well as in the DSS model of inflammatory colitis. Interestingly, by delivering these nanoparticles 
in an alginate hydrogel that was formed by giving a second gavage of CaCl2 as previously 
described(333), we observed intracellular uptake of nanoparticles in both innate and adaptive 
immune cell populations. Oral gavage of DzNP nanoparticles encapsulated in alginate also 
reduced histological scores of inflammation. 
6.2 Characterization of innate and adaptive immune cell function in inflammatory 
mouse models 
 While the studies outlined here utilized well-established models of inflammation to 
understand and parse out the roles of both innate and adaptive immunity, the field of immunology 
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continues to evolve. Immune cells are able to take on specific phenotypes. Future studies must 
focs on determining the biological response to biomaterials and how the individual cell 
populations are modulated can inform future drug development. Our increased understanding of 
the spectrum of cellular phenotypes instructs more sophisticated methods that aim to elucidate the 
origin, activation status, and function of immune cells. Neutrophils, for example, are thought to 
possess distinct subpopulations, and staining cellular markers for flow cytometry is now more 
complex than typical CD11b+ Ly6G+ markers.  
 Similarly, macrophages exhibit remarkable plasticity, and are able to change phenotypes 
in response to their local microenvironment(344). Macrophage phenotypes adapt based on three 
functions: host defense, wound healing, and immune regulation. These macrophages are thought 
to exist on a “spectrum” based on their function. In fact, there may exist more characteristically 
diverse phenotypes of macrophages that have yet to be identified(345). Thus, elucidation of the 
roles of macrophages in response to injury, and in response to immunomodulatory biomaterials, 
is crucial to understanding their function, and to understanding how the innate and adaptive 
immune systems respond.  
 Most relevant from this work is the importance of further characterization of lymphoid 
cell populations. We focused our analysis on CD4+ and CD8+ T-cells, due to their recruitment by 
macrophages and dendritic cells. Importantly, CD4+ and CD8+ cells have been implicated in 
healing(28). However, additional subpopulations of Tregs exist in both CD4+ and CD8+ 
populations, such as Th17, and Gr1+ subpopulations, and we have yet to characterize their 
recruitment or activity following immunomodulatory biomaterial delivery. Future studies should 
focus on characterizing a wider range of cell surface and intracellular markers, especially 
focusing on markers of effector function and activation status. Here, we focused mainly on cell 
numbers, but understanding the expression level of cytokines such as TNF, IL-10, IL-4, and IL-6 
would be useful in establishing how an immune cell is responding to a stimulus, both in the innate 
and adaptive systems. This can be achieved using novel techniques such as mass cytometry or 
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single cell qPCR. Mass cytometry, in particular, is a novel technique that utilizes metal antibodies 
to tag cell surface and intracellular markers. Flow cytometry is limited to 10-15 markers, thus, 
techniques like mass cytometry would vastly expand our knowledge of the immune 
microenvironment in response to injury or in disease. Moreover, analysis of such extensive data 
could be made simple using dimensionality reduction techniques such as SPADE. 
6.3 Further characterization of immune modulation using dimensionality reduction 
techniques 
SPADE is an algorithm that was developed to explore high-dimensional data in an 
objective manner. SPADE helps investigators infer likely cellular progressions and can 
aid in the identification of unexpected cellular behavior or novel types of cells. Here, we 
used SPADE to identify trends in cellular heterogeneity in response to PEG-4MAL 
hydrogels in a chronic injury model, and in response to alginate/chitosan microparticles 
delivering AvrA to the small intestine. In both cases, SPADE was able to recover a 
hierarchy that aligned with our previous work and with known biology. In addition, we 
found trends in cells that we would not have considered to study otherwise.  
 However, SPADE was originally developed to analyze datasets with a large 
number of markers. In our work, we studied at most 12 markers in one panel to 
characterize around 6-7 different cell phenotypes. Future directions should focus on 
developing panels for the purpose of using SPADE to understand cell phenotypes. In the 
original SPADE publication, the authors outline a concept called “progression 
similarity”, where they identified genes that are concordant with hierarchical structure. 
This allows for the selection of protein markers that support a common cellular 
phenotype hierarchy(162). This strategy should be used for future studies that aim to gain 
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an understanding of biological signaling and differentiation processes, and the temporal 
and spatial development of the immune response.  
6.4 Understanding the expansive roles of CD8+ Tregs 
It was our overall goal in this work to use immunomodulatory biomaterials to 
alleviate inflammation in different disease contexts. While we observed the reduction of 
local immune cell recruitment after hydrogel therapy, ultimately, we identified some 
unique subsets of CD8+ T-cells that may be useful in better understanding the CD8+ T-
cell response to injury, biomaterials, and the innate immune response. CD8+ T-
suppressor cells (Tsups or Tregs) are a heterogeneous population, thus making them 
difficult to study using conventional methods, and as a result, are often poorly 
characterized(206). CD8+ Tregs are present in low quantities at steady state in both mice 
and humans. CD8+ Tregs, like CD4+ cells, respond to IL-2 activation, and express 
markers similar to CD4+ Tregs, such as CD103(346) and CTLA-4(347). In fact, CD8+ 
Tregs have been reported in humans, and have a strong immunosuppressive properties in 
vitro(207). CD8+ Tregs have also been shown to play a role in human autoimmune 
disease, including IBD(208). 
On the pro-inflammatory side, this work found the involvement of a subset of 
CD8+ Ly6C+ CD44hi T-cells. Ly6C+ is an activation marker for CD8+ T-cells, and some 
populations of Ly6C+ T-cells have been shown to change their phenotype and function 
from naïve to effector cells(255). Using SPADE was instrumental to our discovery of 
these T-cell subsets responding to our method of delivery. Future analysis of data in 
response to immunomodulatory biomaterials should utilize a separate T-cell panel to 
consider potential contributions from the adaptive immune system, focusing on CD8+ T-
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cells. Moreover, analysis using techniques like mass cytometry would provide useful 
information on the activation status of these cells. Lastly, employing SPADE to analyze 
and elucidate such data would lead to the identification of novel subpopulations of 
adaptive immune cells involved in processes in which they currently are not thought to 
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